<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Amenorrhoea - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Obstetrics & Gynaecology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">66</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 12058,
    "choices": [
      {
        "id": 48196,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Associated with hematometra and hamatocolpos</span></span></span></span></p>"
      },
      {
        "id": 48197,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclic pelvic pain is experienced</span></span></span></span></p>"
      },
      {
        "id": 48198,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast development is absent/ delayed</span></span></span></span></p>"
      },
      {
        "id": 48199,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cruciate incision will relieve symptoms</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old girl presents to OPD and the below examination finding is seen. Which of the following is least likely?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/29/whatsapp-image-2023-04-29-at-154259.jpeg\" style=\"height:321px; width:300px\" /></span></span></p>",
    "unique_key": "Q4471725",
    "question_audio": null,
    "question_video": null,
    "map_id": 12016,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Breast development is absent/ delayed</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The finding here is that of an imperforate hymen</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this there is obstructed outflow to menstrual blood which accumulates in the vagina (hematocolpos) and in the uterus (hematometra) and presents as primary amenorrhoea with presence of secondary sexual characters (as the HPO axis is normal) with a bluish bulge at the introitus. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Associated with Hematometra and Hematocolpos</strong>. An imperforate hymen can lead to the hematocolpos and hematometra due to the obstruction of menstrual flow.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Cyclic Pelvic Pain is Experienced</strong>: The accumulation of menstrual blood in the vagina and uterus often causes cyclic pelvic pain, which coincides with menstrual cycles , known as cryptomenorrhea.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Breast Development is Absent/Delayed</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Least likely. In cases of imperforate hymen, the hypothalamic-pituitary-ovarian (HPO) axis is intact, and normal secondary sexual characteristics, including breast development, are usually present</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Cruciate Incision will Relieve Symptoms</strong>: A cruciate incision of the hymen is a common surgical intervention to relieve symptoms by allowing the accumulated menstrual blood to drain, thus relieving pain and pressure.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In cases of imperforate hymen, patients typically present with symptoms like primary amenorrhea, cyclic pelvic pain, and a bulging hymen due to the accumulation of menstrual blood in the vagina and uterus (hematocolpos and hematometra). These individuals usually have normal secondary sexual development since the hormonal axis is intact. Surgical intervention, such as a cruciate incision of the hymen, is effective in relieving these symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></span></span></p>",
    "correct_choice_id": 48198,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 12060,
    "choices": [
      {
        "id": 48204,
        "text": "<p><span style=\"font-size:12.0pt;\">Transverse vaginal septum</span></p>"
      },
      {
        "id": 48205,
        "text": "<p><span style=\"font-size:12.0pt;\">Imperforate hymen</span></p>"
      },
      {
        "id": 48206,
        "text": "<p><span style=\"font-size:12.0pt;\">MRKH</span></p>"
      },
      {
        "id": 48207,
        "text": "<p><span style=\"font-size:12.0pt;\">Nulliparous prolapse</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 17-year-old girl presents to OPD with cyclic pelvic pain local examination reveals the below image.&nbsp; The diagnosis is?</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture2_D8Jfh1v.jpg\" alt=\"\" width=\"300\" height=\"364\"></span></p>",
    "unique_key": "Q4392056",
    "question_audio": null,
    "question_video": null,
    "map_id": 12017,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. B. Imperforate hymen</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The finding here is that of an imperforate hymen</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In this there is obstructed outflow to menstrual blood which accumulates in the vagina (hematocolpos) and in the uterus (hematometra) and presents as primary amenorrhoea with presence of secondary sexual characters (as the HPO axis is normal) with a bluish bulge at the introitus.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let's look at the other options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Transverse Vaginal Septum</strong>: This is a congenital blockage within the vagina. While it can cause similar symptoms like primary amenorrhea and pelvic pain due to menstrual blood accumulation, <strong>it usually does not present with a bulging, blue perineal membrane as seen in the image.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;C.</strong>&nbsp; <strong>Mayer-Rokitansky-K\u00fcster-Hauser (MRKH) Syndrome</strong>: MRKH syndrome involves congenital absence or underdevelopment of the uterus and vagina. Patients usually present with primary amenorrhea but without cyclic pain or a bulging hymen, as they typically lack functional uterine and upper vaginal tissue.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D</strong>.&nbsp;<strong>Nulliparous Prolapse</strong>: Nulliparous prolapse, or pelvic organ prolapse in a woman who has not given birth, would not present with a bulging, blue membrane at the vaginal entrance and is unrelated to primary amenorrhea or cyclic pelvic pain.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">An imperforate hymen presents with primary amenorrhea, cyclic pelvic pain, and a bulging, blue hymenal membrane, indicating hematocolpos (accumulation of menstrual blood in the vagina). This condition can be relieved by surgical incision of the hymen to allow for normal menstrual flow.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorhea</strong></span></p>",
    "correct_choice_id": 48205,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 12061,
    "choices": [
      {
        "id": 48208,
        "text": "<p><span style=\"font-size:12.0pt;\">Transverse vaginal septum</span></p>"
      },
      {
        "id": 48209,
        "text": "<p><span style=\"font-size:12.0pt;\">Imperforate hymen</span></p>"
      },
      {
        "id": 48210,
        "text": "<p><span style=\"font-size:12.0pt;\">Mullerian agenesis</span></p>"
      },
      {
        "id": 48211,
        "text": "<p><span style=\"font-size:12.0pt;\">OHVIRA syndrome</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 16-year-old girl presents to OPD with primary amenorrhea and cyclic pelvic pain. On rectal examination, a bulge is felt anteriorly, 4 cm above the anal verge. The likely diagnosis is:</span></p>",
    "unique_key": "Q3431357",
    "question_audio": null,
    "question_video": null,
    "map_id": 12018,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. A. Transverse vaginal septum</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A transverse vaginal septum is the most likely diagnosis as she has primary amenorrhoea with cyclical pelvic pain thereby pointing to a complete obstruction to the outflow of menstrual blood. A rectal exam showing the obstruction high up indicates that the obstruction is higher up in the vagina, thereby pointing to a transverse vaginal septum</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Other options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B:&nbsp;</strong>Imperforate hymen will have a bulge at the introitus. And on per rectal examination, swelling will be palpable from anal verge.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C:&nbsp;</strong>MRKH has a vaginal dimple, and no bulge will be felt on per rectal examination</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D:&nbsp;</strong>OHVIRA: obstructed hemi vagina and ipsilateral renal agenesis is a syndrome characterized by uterus didelphys, unilateral vaginal obstruction, and ipsilateral renal agenesis. The patient has normal menses from one hemi uterus and features of cyclic pelvic pain and hematocolpos on side of obstructed hemivagina.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-105747.jpg\" alt=\"\" width=\"500\" height=\"527\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Thus <strong>option A.</strong> transverse vaginal septum is correct&nbsp; based on the description ,since the bulge is not at the introitus but higher up.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A transverse vaginal septum presents with primary amenorrhea and cyclic pelvic pain due to hematocolpos formation above the level of the obstruction. Diagnosis is suggested by a normal vaginal orifice and a palpable mass on rectal examination. Recognition and surgical treatment of this congenital anomaly are essential to relieve symptoms and prevent long-term complications.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48208,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12062,
    "choices": [
      {
        "id": 48212,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OHVIRA syndrome</span></span></span></span></p>"
      },
      {
        "id": 48213,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRKH syndrome</span></span></span></span></p>"
      },
      {
        "id": 48214,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACUM </span></span></span></span></p>"
      },
      {
        "id": 48215,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Robert&rsquo;s uterus</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old woman presents to OPD with painful menstruation. On examination, normal secondary sexual characters are present. The vagina is patent but shows a bulge on the right side near the cervix. On per rectal examination, there is a bulge felt about 4 cm from anal verge and is more towards left side. On Ultrasound, there is hematocolpos and the left side kidney is absent. </span></span><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnosis is: </span></span></span></span></p>",
    "unique_key": "Q5485439",
    "question_audio": null,
    "question_video": null,
    "map_id": 12019,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. OHVIRA syndrome</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Options A. OHVIRA:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">obstructed hemi vagina and ipsilateral renal agenesis is a syndrome characterized by uterus didelphys, unilateral vaginal obstruction, and ipsilateral renal agenesis. The patient has normal menses from one hemi uterus and features of cyclic pelvic pain and hematocolpos on side of obstructed hemivagina. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-105747_O1cNPjD.jpg\" style=\"height:527px; width:500px\" /></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRKH syndrome can have absent kidney / renal and skeletal abnormalities but usually does not have hematocolpos</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACUM is an accessory and cavitated uterine horn. Patients present with dysmenorrhea and features similar to endometriosis. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robert uterus is a rare uterine anomaly with asymmetrical uterine septum resulting in obstructed hemi cavity resulting in hematometra on one side. Patient has normal menses with dysmenorrhea. No bulge in vagina will be felt. On per rectal examination, the bulge may not be palpable as mostly hematometra and hematosalpinx is more likely and there is no hematocolpos. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-110058.jpg\" style=\"height:321px; width:400px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: OHVIRA syndrome is characterized by a uterine anomaly such as uterine didelphys with obstructed hemivagina leading to hematocolpos, often accompanied by ipsilateral renal agenesis. This syndrome should be considered in patients presenting with painful menstruation, a unilateral vaginal bulge, and corresponding renal anomalies on imaging. Diagnosis and management of OHVIRA syndrome are crucial for alleviating symptoms and addressing potential reproductive complications.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></p>",
    "correct_choice_id": 48212,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12063,
    "choices": [
      {
        "id": 48216,
        "text": "<p><span style=\"font-size:12.0pt;\">Complete AIS</span></p>"
      },
      {
        "id": 48217,
        "text": "<p><span style=\"font-size:12.0pt;\">Partial AIS</span></p>"
      },
      {
        "id": 48218,
        "text": "<p><span style=\"font-size:12.0pt;\">MRKH</span></p>"
      },
      {
        "id": 48219,
        "text": "<p><span style=\"font-size:12.0pt;\">Swyer syndrome</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 18 year old girl presents to OPD with primary amenorrhea, normal breast and pubic &amp; axillary hair development. On examination, vagina is absent. Serum estradiol and FSH level are normal. USG shows absent uterus and vagina. The likely diagnosis is:</span></p>",
    "unique_key": "Q8503163",
    "question_audio": null,
    "question_video": null,
    "map_id": 12020,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ans. C. MRKH</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">This is a case of MRKH (mullerian agenesis) with inguinal hernia</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Normal secondary sexual characteristics, absent vagina and absent uterus, normal hormones point towards MRKH.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">They exhibit normal, symmetrical breast and pubic hair development,</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">have no visible vagina and have no symptoms or signs of cryptomenorrhea because the rudimentary uteri contain no functional endometrium.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Renal and skeletal abnormalities may be associated.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">The ovaries are entirely normal histologically and functionally, although their location in the pelvis may be higher, positioned at or even above the level of the pelvic brim; one or both also may be hypoplastic or associated with an inguinal hernia. </span><span style=\"background-color:transparent;font-size:16px;\">Inguinal hernia is rare in MRKH, but known due to ectopic ovaries</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;A.</strong>&nbsp;<strong>Complete Androgen Insensitivity Syndrome (AIS)</strong>: In complete AIS, individuals have a 46,XY karyotype and testes, but due to a complete inability to respond to androgens, they develop female external genitalia. However, they typically have normal breast development <strong>but no pubic or axillary hair</strong>. The presence of normal pubic and axillary hair development makes complete AIS less likely in this case.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;B.</strong>&nbsp;<strong>Partial AIS</strong>: Partial AIS involves some degree of androgen insensitivity, leading to a spectrum of genital ambiguity. The presence of normal female secondary sexual characteristics and an inguinal hernia may be consistent with partial AIS, but the absent uterus and vagina are not typical for this condition.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;D.</strong>&nbsp;<strong>Swyer Syndrome</strong>: Swyer syndrome, or 46XY pure gonadal dysgenesis, presents with a 46XY karyotype and streak gonads but with female external genitalia. Individuals typically have primary amenorrhea and underdeveloped secondary sexual characteristics due to the lack of functional ovaries. The presence of normal breast development and pubic/axillary hair makes this diagnosis less likely.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">In cases of primary amenorrhea with normal female secondary sexual characteristics and the absence of the uterus and vagina, Mayer-Rokitansky-K\u00fcster-Hauser syndrome is a likely diagnosis. MRKH syndrome is characterized by the congenital absence of the uterus and upper vagina while maintaining normal ovarian function and external secondary sexual characteristics.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48218,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12064,
    "choices": [
      {
        "id": 48220,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vaginoplasty</span></span></span></span></p>"
      },
      {
        "id": 48221,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vaginoplasty, and IVF with self-oocyte and surrogacy</span></span></span></span></p>"
      },
      {
        "id": 48222,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vaginoplasty and IVF with donor oocyte and surrogacy</span></span></span></span></p>"
      },
      {
        "id": 48223,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vaginoplasty and donor embryo and surrogacy</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old girl presents to OPD with primary amenorrhea and evaluation reveals MRKH. Treatment for patients with MRKH includes: </span></span></span></span></p>",
    "unique_key": "Q4673613",
    "question_audio": null,
    "question_video": null,
    "map_id": 12021,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Vaginoplasty, and IVF with self-oocyte and surrogacy</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The 2 goals of treatment in MRKH syndrome are: Sexual function and Fertility</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sexual function</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Creation of a functional vagina. This can be achieved</span></span></span></span>\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li style=\"text-align:left\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Surgically &ndash; McIndoe&rsquo;s vaginoplasty</span></span></span></span></li>\r\n\t\t\t<li style=\"text-align:left\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-surgical: Using vaginal dilators (Fran dilators)</span></span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fertility</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Advances in assisted reproductive technologies with the use of gestational surrogacy option have allowed attainment of genetic offspring by in vitro fertilization (IVF) using oocytes retrieved from their own normal ovaries and the sperm of their chosen partner, with subsequent transfer of embryos to a gestational surrogate.</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the past decade, uterine transplantation has moved leaps and bounds, may emerge as a treatment option.</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Let&#39;s look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Vaginoplasty</strong>: This treatment alone does not address the issue of fertility, as these patients typically lack a functional uterus.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Vaginoplasty, and IVF with Self-Oocyte and Surrogacy</strong>: Correct. This option includes vaginoplasty to create a vagina and the use of in vitro fertilization (IVF) with the patient&#39;s own oocytes. Because women with MRKH typically have normal ovaries, they can produce eggs for IVF. The fertilized embryos can then be carried by a surrogate mother, as patients with MRKH lack a uterus.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Vaginoplasty and IVF with Donor Oocyte and Surrogacy</strong>: This option is not typically necessary for MRKH patients, as they usually have functional ovaries and can use their own oocytes for IVF. The use of donor oocytes would be considered if there were an issue with the patient&#39;s egg quality or quantity.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Vaginoplasty and Donor Embryo and Surrogacy</strong>: Similar to option C, this approach would only be necessary if there were issues with the patient&#39;s oocytes. As women with MRKH generally have normal ovarian function, they can typically use their own oocytes for IVF.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: For patients with MRKH syndrome, treatment can include vaginoplasty to construct a functional vagina and IVF using self-oocytes, with the embryo being carried by a surrogate mother. This approach addresses both the anatomical challenge of the absent vagina and the issue of fertility due to the absence of a functional uterus.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></p>",
    "correct_choice_id": 48221,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 12065,
    "choices": [
      {
        "id": 48224,
        "text": "<p><span style=\"font-size:12.0pt;\">Karyotype will most likely be 46XX</span></p>"
      },
      {
        "id": 48225,
        "text": "<p><span style=\"font-size:12.0pt;\">Associated with renal and skeletal anomalies</span></p>"
      },
      {
        "id": 48226,
        "text": "<p><span style=\"font-size:12.0pt;\">Gonadectomy and vaginoplasty are recommended treatment</span></p>"
      },
      {
        "id": 48227,
        "text": "<p><span style=\"font-size:12.0pt;\">Immediate Gonadectomy is done immediately</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 20-year-old girl presents to OPD with primary amenorrhea. Height is 160 cm, has normal breast development and absent pubic hair. The uterus and vagina are absent. Which of the following is true?</span></p>",
    "unique_key": "Q4930693",
    "question_audio": null,
    "question_video": null,
    "map_id": 12022,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. C. Gonadectomy and vaginoplasty are recommended treatment</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The presented case is of Androgen Insensitivity Syndrome</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Patients with complete AIS most commonly present after the age of puberty in late adolescence or as young adults with primary amenorrhea. They exhibit asymmetrical secondary sexual development (breast development with absent or scant pubic hair), have a short vagina with no visible cervix, and have no other symptoms or complaints.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Serum testosterone concentration easily distinguishes patients with AIS from those with M\u00fcllerian agenesis because levels are normal or modestly elevated well above the normal range for females and often above the range observed in normal males. Serum LH levels also are elevated, reflecting androgen insensitivity at the hypothalamus-pituitary level. A karyotype (46XY) firmly establishes the diagnosis.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In patients with AIS, the options for creation of a neovagina are the same as for those with M\u00fcllerian agenesis</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Complete AIS is the only exception to the rule that gonads with a Y chromosome should be removed as soon as the diagnosis is made.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let's evaluate each option:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Karyotype will most likely be 46XX</strong>: False. The presence of normal breast development and absent pubic hair suggests Androgen Insensitivity Syndrome (AIS), where the karyotype is typically 46XY. Mullerian agenesis will have pubic hair development</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Associated with renal and skeletal anomalies</strong>: False. While renal and skeletal anomalies are commonly associated with MRKH syndrome, they are not a typical feature of Androgen Insensitivity Syndrome (AIS). Mullerian agenesis will have pubic hair development</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Gonadectomy and Vaginoplasty are recommended treatment</strong>: Correct for AIS. Patients with complete AIS have testes that produce normal to high levels of testosterone, which gets converted to estrogen, leading to breast development. However, the body is insensitive to testosterone, resulting in scant or absent pubic hair. Gonadectomy is recommended to prevent the risk of gonadal tumors. Vaginoplasty may be performed for the creation of a functional vagina.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Immediate Gonadectomy is done immediately</strong>: Immediate gonadectomy is not typically recommended in complete AIS. It is usually delayed until after puberty to allow for natural estrogen production from the testes, which contributes to female secondary sexual characteristics. Incomplete AIS may require earlier gonadectomy due to a higher risk of gonadal tumors.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In Androgen Insensitivity Syndrome (AIS), which is characterized by a 46XY karyotype, patients typically present with primary amenorrhea, normal breast development, and scant pubic hair due to insensitivity to androgens. Gonadectomy is recommended to prevent gonadal tumor risk, often after puberty to benefit from endogenous estrogen production for sexual development. Vaginoplasty is an option for those who wish to have a functional vagina.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48226,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12067,
    "choices": [
      {
        "id": 48232,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal anomalies</span></span></span></span></p>"
      },
      {
        "id": 48233,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skeletal anomalies</span></span></span></span></p>"
      },
      {
        "id": 48234,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inguinal hernia </span></span></span></span></p>"
      },
      {
        "id": 48235,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clitoromegaly</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 21-year-old girl presents to OPD with primary amenorrhea, she has normal breast development and scant pubic hair. Labia minora are small and vagina is absent. Which of the following is most likely to be associated with this: </span></span></p>",
    "unique_key": "Q5561905",
    "question_audio": null,
    "question_video": null,
    "map_id": 12024,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Inguinal hernia </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given clinical picture is of complete AIS. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The gonads are testes, and their location may be intra-abdominal, but often are partially descended into the inguinal canal, more than half of patients with complete AIS have an inguinal hernia, and the testes are frequently palpable in the inguinal canals, most commonly at the level of the external inguinal ring.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Renal Anomalies</strong>: They are more commonly associated with conditions like Mayer-Rokitansky-K&uuml;ster-Hauser (MRKH) syndrome, not typically with Complete Androgen Insensitivity Syndrome (AIS).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Skeletal Anomalies</strong>: Also seen more frequently in MRKH syndrome not in AIS. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Inguinal Hernia</strong>: Correct. In Complete AIS, the individual has a 46XY karyotype with testes that may be located in the inguinal canal, leading to a higher likelihood of inguinal hernias. More than half of patients with Complete AIS have an inguinal hernia, and the testes are often palpable in the inguinal canals.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Clitoromegaly</strong>: Clitoromegaly is more commonly associated with conditions that involve exposure to higher levels of androgens, such as Congenital Adrenal Hyperplasia (CAH). It is not typically a feature of Complete AIS, where there is insensitivity to androgens.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In Complete Androgen Insensitivity Syndrome (AIS), patients with a 46,XY karyotype present with female external genitalia, normal breast development, and absent or scant pubic hair due to insensitivity to androgens. A common associated condition is the presence of inguinal hernias, as the testes may be located in the inguinal canal. Understanding the clinical presentation and associated features of Complete AIS is essential for accurate diagnosis and appropriate management.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></span></span></p>",
    "correct_choice_id": 48234,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12071,
    "choices": [
      {
        "id": 48248,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46 XX</span></span></span></span></p>"
      },
      {
        "id": 48249,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46XY</span></span></span></span></p>"
      },
      {
        "id": 48250,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45 X0</span></span></span></span></p>"
      },
      {
        "id": 48251,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">47 XXY</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 14-year-old girl presents to OPD with primary amenorrhea. Her height is 135 cm. She has a webbed neck and increased carrying angle. Breast development is tanner 1 with widely spaced nipple, external genitalia are infantile. The Karyotype is most likely to reveal: </span></span></p>",
    "unique_key": "Q7273216",
    "question_audio": null,
    "question_video": null,
    "map_id": 12027,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. 45 X0</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a case of Turner syndrome. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Short stature, widely spaced nipple, short fourth metacarpals, increased carrying angle are typical features of Turner syndrome. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype is 45X0. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mosaics of 45X0/46XX or 45 X0/46XY may exist. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>46 XX</strong>: Normal female karyotype. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>46 XY</strong>: Normal male karyotype. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>47 XXY</strong>: This karyotype is associated with Klinefelter syndrome, which is characterized by a male phenotype with some level of hypogonadism and gynecomastia, not matching the clinical presentation described in the girl.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In a patient presenting with primary amenorrhea, short stature, webbed neck, widely spaced nipples, and infantile external genitalia, the karyotype most likely to be found is 45 X0, indicative of Turner syndrome. Turner syndrome is characterized by the absence of all or part of a second sex chromosome, leading to various developmental and physical abnormalities. Identification of this condition is crucial for appropriate management and support.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></p>",
    "correct_choice_id": 48250,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 12073,
    "choices": [
      {
        "id": 48256,
        "text": "<p><span style=\"font-size:12.0pt;\">Estrogen therapy</span></p>"
      },
      {
        "id": 48257,
        "text": "<p><span style=\"font-size:12.0pt;\">Cyclic Estrogen and progesterone therapy</span></p>"
      },
      {
        "id": 48258,
        "text": "<p><span style=\"font-size:12.0pt;\">Growth hormone and Estrogen therapy</span></p>"
      },
      {
        "id": 48259,
        "text": "<p><span style=\"font-size:12.0pt;\">Growth hormone and cyclic Estrogen-progesterone therapy</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 13-year-old girl with primary amenorrhea, short stature, and hypergonadotropic hypogonadism. Karyotype reveals 45X0. What is the next line of management?</span></p>",
    "unique_key": "Q4934599",
    "question_audio": null,
    "question_video": null,
    "map_id": 12029,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ans. C. Growth hormone and Estrogen therapy</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">With early diagnosis and treatment with growth hormone (GH), a final height greater than 150 cm can be achieved in most patients with Turner syndrome.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">The most important determinants of final height are the dose of GH and the duration of treatment before estrogen therapy begins.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Treatment with GH generally should begin as soon as growth curve falls below the fifth percentile of normal female growth, and the regimen must be individualized, according to response.&nbsp;</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Treatment with estrogen must be timed carefully, with the goals of minimizing its adverse effects on growth and adult height and inducing puberty at an approximately normal age.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Ideally, estrogen therapy should begin no later than age 15 and not before age 12 when growth is a priority, unless height already has been maximized.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Estrogen therapy should begin at a low dose (e.g., 0.25-0.5 mg micronized oestradiol or its equivalent), increasing gradually at intervals of 3-6 months according to response (Tanner stage, bone age), with the goal of completing sexual maturation over a period of 2-3 years.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>When vaginal bleeding first occurs, or after 12-24 months of estrogen therapy, a progestin (e.g., MPA) should be added to the treatment regimen to prevent dysfunctional bleeding, to achieve differentiation of breast tissue, and to protect the endometrium from long-term adverse effects of unopposed estrogen</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Let's explore each option:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;A.</strong>&nbsp;<strong>Estrogen Therapy</strong>: Estrogen therapy is used in Turner syndrome to induce secondary sexual characteristics and maintain female sex hormone levels. However, initiating estrogen therapy alone may not address short stature, a common issue in Turner syndrome.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;B</strong>.&nbsp;<strong>Cyclic Estrogen and Progesterone Therapy</strong>: This therapy is appropriate for inducing and maintaining secondary sexual characteristics and menstrual cycles. However, it does not address the short stature associated with Turner syndrome. </span><span style=\"background-color:transparent;font-size:16px;\">Full HRT is used later after height is optimized.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;C.</strong>&nbsp;<strong>Growth Hormone and Estrogen Therapy</strong>: Correct. Growth hormone therapy is recommended to address short stature in Turner syndrome. It should ideally begin as early as possible, and estrogen therapy should be initiated carefully to induce puberty without adversely affecting growth.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;D</strong>.&nbsp;<strong>Growth Hormone and Cyclic Estrogen-Progesterone Therapy</strong>: While this combination addresses both growth and the development of secondary sexual characteristics, the initiation of cyclic estrogen-progesterone therapy may be deferred until after maximizing height with growth hormone therapy.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">For a patient with Turner syndrome presenting with short stature and primary amenorrhea, the recommended management includes growth hormone therapy to address short stature and estrogen therapy to induce secondary sexual characteristics. The timing and dosage of estrogen therapy are critical to balance the induction of puberty with the potential impact on growth. Growth hormone therapy should ideally begin when the growth curve falls below the fifth percentile, and estrogen therapy should start between the ages of 12 and 15, gradually increasing over time</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48258,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 12075,
    "choices": [
      {
        "id": 48264,
        "text": "<p><span style=\"font-size:12.0pt;\">Karyotype</span></p>"
      },
      {
        "id": 48265,
        "text": "<p><span style=\"font-size:12.0pt;\">Cyclic Estrogen and progesterone</span></p>"
      },
      {
        "id": 48266,
        "text": "<p><span style=\"font-size:12.0pt;\">Gonadectomy</span></p>"
      },
      {
        "id": 48267,
        "text": "<p><span style=\"font-size:12.0pt;\">Vaginoplasty</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 17-year-old girl presents to OPD for not having attained menses till now. On examination, height is 170 cm, breasts are not well developed, pubic hair are absent, external genitalia are normal and vagina and uterus are present. Serum FSH is high. What is the next step?</span></p>",
    "unique_key": "Q6172086",
    "question_audio": null,
    "question_video": null,
    "map_id": 12030,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. A. Karyotype</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The clinical picture is of Swyer syndrome. (46XY dysgenesis)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">But to differentiate it from 46 XX gonadal dysgenesis or premature ovarian failure, a karyotype must be done before proceeding with gonadectomy.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let us look at each option:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Karyotype</strong>: Correct. Given the clinical presentation, a karyotype test is essential to determine the chromosomal pattern, which will help in diagnosing conditions like Swyer syndrome (46,XY gonadal dysgenesis) or other forms of gonadal dysgenesis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;B</strong>.&nbsp;<strong>Cyclic Estrogen and Progesterone</strong>: Hormone replacement therapy with estrogen and progesterone may be necessary to induce secondary sexual characteristics and regular menstrual cycles, but it should only be initiated after a definitive diagnosis is made via karyotyping.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;</strong></span><span style=\"font-size:12pt;\"><strong>C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Gonadectomy</strong>: Gonadectomy may be indicated in cases of Swyer syndrome due to the increased risk of gonadoblastoma in streak gonads. However, this should only be considered after a definitive diagnosis is confirmed through karyotyping.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D</strong>.&nbsp;<strong>Vaginoplasty</strong>: Vaginoplasty is a surgical procedure to create or reconstruct a vagina. This is not indicated in this case, as the patient has a normal vagina and external genitalia.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>: In a patient with primary amenorrhea, underdeveloped breasts, and elevated serum FSH, karyotyping is the next essential step to differentiate between conditions like Swyer syndrome (46,XY gonadal dysgenesis) and other forms of gonadal dysgenesis. This will guide further management, including the possibility of hormone replacement therapy or gonadectomy, depending on the diagnosis</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref:&nbsp;Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48264,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12076,
    "choices": [
      {
        "id": 48268,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen insensitivity syndrome</span></span></span></span></p>"
      },
      {
        "id": 48269,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Constitutional delay</span></span></span></span></p>"
      },
      {
        "id": 48270,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Functional hypothalamic amenorrhoea</span></span></span></span></p>"
      },
      {
        "id": 48271,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mullerian agenesis</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16y girl is brought to the OPD as she has not started her period. The patients 14y sister underwent menarche 2 years earlier and her mother began menstruating at age 13. She has no weight gain, headaches, nipple discharge or abdominal pain. She is not sexually active and is not using any method of contraception. She is physically active and is on her school&rsquo;s basketball team. Her breast exam and pubic hair are Tanner stage IV. The abdomen is soft. The external genitalia appear normal. The vagina ends in a blind pouch. An ultrasound reveals ovaries, but no cervix or uterus is seen. Which is the most likely diagnosis?</span></span></span></span></p>",
    "unique_key": "Q1834105",
    "question_audio": null,
    "question_video": null,
    "map_id": 12031,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Mullerian agenesis</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mullerian agenesis is also known as MRKH syndrome</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is no Mullerian structure (Absent uterus, cervix, fallopian tubes, upper 2/3<sup>rd</sup> of vagina) but ovaries are present</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">So patient presents as primary amenorrhoea with normal secondary sexual characters</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All hormonal levels are normal</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skeletal and renal anomalies may be associated</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype: 46XX</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fertility: Surrogacy, uterine transplant (upcoming)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sexual: Vaginoplasty</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Androgen Insensitivity Syndrome</strong>: 46XY karyotype develop female external genitalia due to androgen receptor insensitivity. However, breast development is usually normal or above average due to peripheral conversion of androgens to estrogens. The presence of Tanner stage IV breast development and pubic hair is less typical for AIS, which usually presents with scant or absent pubic hair.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Constitutional Delay</strong>: A variation of normal development where puberty and associated milestones, such as menarche, occur later than average. However, the presence of Tanner stage IV breast development and pubic hair indicates that puberty has progressed, making this less likely.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Functional Hypothalamic Amenorrhea: This</strong> is associated with stress, significant weight loss, or excessive exercise and results in suppressed gonadotropin-releasing hormone (GnRH) secretion. This diagnosis is less likely given the patient&#39;s normal development of secondary sexual characteristics and absence of weight loss or other stress factors.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In a patient with primary amenorrhea, normal secondary sexual development, and a blind-ending vaginal pouch with absent uterus and cervix on ultrasound, M&uuml;llerian agenesis is the most likely diagnosis. This condition is characterized by the congenital absence of the uterus and part of the vagina while maintaining normal ovarian function and external genitalia. Diagnosis is crucial for appropriate management and support.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></span></span></p>",
    "correct_choice_id": 48271,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12078,
    "choices": [
      {
        "id": 48276,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">47XXY</span></span></span></span></p>"
      },
      {
        "id": 48277,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46 XY</span></span></span></span></p>"
      },
      {
        "id": 48278,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45 XO</span></span></span></span></p>"
      },
      {
        "id": 48279,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46 XX</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15y old is brought to the OPD by her mother due to concerns that her mother has not had her menses. She was born at 36 weeks and has had no developmental delay. She is doing well in school and plays on the tennis team. She is healthy and takes no medications. She is not sexually active. She does not consume alcohol or smoke. Her maternal aunt has primary infertility and maternal grandmother had ovarian cancer. Her height is 5&rsquo;7 and weight is 63kg. There is no acne or hirsutism. Breast dev is Tanner stage 5. There is scanty axillary and pubic hair. On pelvic exam, external genitalia appear normal and speculum shows a blind vaginal pouch. On ultrasound, uterus and ovaries are absent. What is the likely karyotype?</span></span></span></span></p>",
    "unique_key": "Q2542491",
    "question_audio": null,
    "question_video": null,
    "map_id": 12032,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B.&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46 XY</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient has androgen insensitivity syndrome</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a X linked recessive condition where the genotype is 46XY. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenotypically they are female.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Testes produce both AMH and testosterone.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Testosterone has no activity on peripheral tissues. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AMH causes regression of mullerian structures. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These patients present as:</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary amenorrhoea</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast development</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal female external genitalia</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s explore the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>47XXY</strong>: Associated with Klinefelter syndrome, typically presents in males with small testes, reduced secondary sexual characteristics, infertility, and sometimes gynecomastia. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>45XO</strong>: Associated with Turner syndrome, typically presenting with short stature, primary amenorrhea, and sometimes other physical anomalies. Turner syndrome patients usually have underdeveloped secondary sexual characteristics.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>46XX</strong>: This is a normal female karyotype. The clinical features described, particularly the absence of the uterus and ovaries and the presence of normal breast development with scanty axillary and pubic hair, are not typical for a 46XX karyotype.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In a patient presenting with primary amenorrhea, normal breast development, scanty body hair, normal external genitalia, and absence of the uterus and ovaries, the likely diagnosis is Androgen Insensitivity Syndrome (AIS), associated with a 46XY karyotype. Patients with AIS develop female external genitalia due to their body&#39;s insensitivity to androgens. Understanding the karyotype and associated clinical features is essential for diagnosis and management</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 376, DC Duttas&rsquo;s Textbook of Gynecology 8<sup>th</sup> edition</span></span></strong></p>",
    "correct_choice_id": 48277,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12079,
    "choices": [
      {
        "id": 48280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype</span></span></span></span></p>"
      },
      {
        "id": 48281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI brain</span></span></span></span></p>"
      },
      {
        "id": 48282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pelvic USG</span></span></span></span></p>"
      },
      {
        "id": 48283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reassurance </span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 14y girl is brought to the OPD as she has not yet attained her period. She has no headache, nipple discharge or abdominal pain. She takes a topical retinoid and a topical antibiotic for acne. Her last visit was 3 months ago for evaluation of gastroenteritis. Her mother is diabetic. She has 2 older sisters both of whom underwent menarche at 13 years. Since the last appointment, her height has increased by 5 cm. Examination shows acne on the face. Breast development and pubic hair are tanner stage 4. What is the next best step?</span></span></span></span></p>",
    "unique_key": "Q5348204",
    "question_audio": null,
    "question_video": null,
    "map_id": 12033,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Reassurance</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient is 14y with normal secondary sexual characters</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">She also has a growth spurt </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is most likely constitutional </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No further investigations are warranted</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Re-evaluate if menarche does not occur by age 15y</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Karyotype</strong>: Karyotyping is used to identify chromosomal abnormalities, typically indicated in cases of abnormal sexual development or primary amenorrhea. Normal Tanner stage 4 development makes a chromosomal abnormality less likely.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>MRI Brain</strong>: Particularly the pituitary region, is indicated in cases where there are symptoms suggestive of a central cause of amenorrhea, such as headaches or visual changes. This patient does not have such symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pelvic Ultrasound (USG)</strong>: It is useful for evaluating the internal reproductive organs. However, given this patient&#39;s normal secondary sexual development and lack of other concerning symptoms, it may not be immediately necessary.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Reassurance</strong>: Correct. The patient shows normal secondary sexual characteristics and a recent growth spurt, which suggests that she is progressing normally through puberty. Primary amenorrhea at this stage, especially given her normal development, is likely constitutional and not immediately concerning. Reassurance and observation are appropriate, with re-evaluation recommended if menarche does not occur by age 15.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In a 14-year-old girl with primary amenorrhea but normal secondary sexual development and recent growth, reassurance and observation are appropriate initial steps. Most girls experience menarche by age 15, and the absence of menarche by this age would warrant further evaluation. It&#39;s important to consider the normal variability in the timing of pubertal milestones when assessing adolescents.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 376, DC Duttas&rsquo;s Textbook of Gynecology 8<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48283,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 12081,
    "choices": [
      {
        "id": 48288,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">12-year-old with Tanner stage I breast development</span></span></span></span></p>"
      },
      {
        "id": 48289,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">16-year-old with Tanner stage II breast development </span></span></span></span></p>"
      },
      {
        "id": 48290,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">14-year-old with Tanner stage III breast development </span></span></span></span></p>"
      },
      {
        "id": 48291,
        "text": "<p><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">18-year-old with Tanner stage V breast development and cessation of menses for the last two cycles</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following clinical scenarios meets the definition of amenorrhea?</span></span></span></span></p>",
    "unique_key": "Q7976684",
    "question_audio": null,
    "question_video": null,
    "map_id": 12035,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 16-year-old with Tanner stage II breast development </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Definition of primary amenorrhoea is:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Failure to attain menarche by the age of 13y in the absence of secondary sexual characters OR</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Failure to attain menarche by the age of 15y in the presence of secondary sexual characters</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Definition of secondary amenorrhoea</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cessation of periods for 6 months or 3 or more periods</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The only option which fulfils these criteria is option &ldquo;B&rdquo; i.e., 16y old with Tanner stage 2 breast development</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look&nbsp; at each option :</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. 12-year-old with Tanner Stage I Breast Development</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: within the normal range for a girl to not have achieved menarche, especially with Tanner Stage I breast development, indicating early puberty.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>16-year-old with Tanner Stage II Breast Development</strong>: Correct. According to the definition, primary amenorrhea is the failure to attain menarche by age 15 with the presence of secondary sexual characteristics. A 16-year-old with Tanner Stage II breast development meets this criterion for primary amenorrhea.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. 14-year-old with Tanner Stage III Breast Development</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: development is still within the normal range for not having achieved menarche.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>18-year-old with Tanner Stage V Breast Development and Cessation of Menses for the Last Two Cycles</strong>: This scenario describes secondary amenorrhea, which is defined as the cessation of menses for six months or the absence of three or more consecutive menstrual cycles. Since the cessation in this case is only for two cycles, it does not meet the definition of secondary amenorrhea.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Primary amenorrhea is defined as the absence of menarche by age 15 in the presence of secondary sexual characteristics or by age 13 in the absence of secondary sexual characteristics. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></span></span></p>",
    "correct_choice_id": 48289,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 12082,
    "choices": [
      {
        "id": 48292,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovary</span></span></span></span></p>"
      },
      {
        "id": 48293,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Testis</span></span></span></span></p>"
      },
      {
        "id": 48294,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paroophoron</span></span></span></span></p>"
      },
      {
        "id": 48295,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epoophoron</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old nulligravid female presents with primary amenorrhea. During examination, Tanner stage 4 breast development and sparse pubic and axillary hair are noted. Also, a blind-ending vagina is identified. The patient undergoes a laparoscopy. The white oval structure seen represents what? </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture6_FJDDIEk.jpg\" style=\"height:240px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7342940",
    "question_audio": null,
    "question_video": null,
    "map_id": 12036,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Testis</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The scenario given is most likely androgen insensitivity syndrome</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The structure shown is the male gonad (testis)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These need to be removed (gonadectomy) as the incidence of malignancy is very high.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s consider each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ovary</strong>: In typical female anatomy, ovaries are present. However, the clinical features described here, including the blind-ending vagina and sparse body hair despite breast development, are not consistent with typical female internal genital anatomy.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Testis</strong>: Correct. This scenario is indicative of Androgen Insensitivity Syndrome (AIS), a condition where an individual with a 46XY karyotype develops female external genitalia. In AIS, the gonads are testes, not ovaries. The risk of gonadal malignancy warrants their removal.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Paroophoron</strong>: The paroophoron (of Johnson) is also a remnant of the Mesonephric duct. It is situated between the epoophoron and the uterus.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Epoophoron</strong>: The&nbsp;<strong>epoophoron</strong>&nbsp;(also called&nbsp;<strong>organ of Rosenm&uuml;ller</strong>&nbsp;or the&nbsp;<strong>parovarium</strong>) is a remnant of the&nbsp;Mesonephric duct&nbsp;that can be found next to the&nbsp;ovary&nbsp;and&nbsp;fallopian tube.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In a patient with primary amenorrhea, female external genitalia, but with internal male gonads (testes), the diagnosis of Androgen Insensitivity Syndrome should be considered. These patients have a 46XY karyotype and testes that are typically undescended. Due to the risk of gonadal malignancy, gonadectomy is recommended</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 376, DC Duttas&rsquo;s Textbook of Gynecology 8<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48293,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 12083,
    "choices": [
      {
        "id": 48296,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male level</span></span></span></span></p>"
      },
      {
        "id": 48297,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Female level</span></span></span></span></p>"
      },
      {
        "id": 48298,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Not measurable</span></span></span></span></p>"
      },
      {
        "id": 48299,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Significantly elevated (&gt;1000 ng/dL)</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the expected testosterone level in a patient with mullerian agenesis?</span></span></p>",
    "unique_key": "Q9838249",
    "question_audio": null,
    "question_video": null,
    "map_id": 12037,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Female level</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mullerian agenesis is also known as MRKH syndrome</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is no Mullerian structure (Absent uterus, cervix, fallopian tubes, upper 2/3<sup>rd</sup> of vagina) but ovaries are present</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">So, patient presents as primary amenorrhoea with normal secondary sexual characters</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All hormonal levels are normal (so testosterone will be as of female level)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skeletal and renal anomalies may be associated</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype: 46XX</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment:</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fertility: Surrogacy, uterine transplant (upcoming)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sexual: Vaginoplasty</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. Male Level</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This would be expected in conditions like Androgen Insensitivity Syndrome, where individuals have a 46XY karyotype and testes that produce male levels of testosterone.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Female Level</strong>: Correct. In M&uuml;llerian agenesis (Mayer-Rokitansky-K&uuml;ster-Hauser syndrome), the individuals usually have a 46XX karyotype and ovaries that produce female levels of hormones, including testosterone. Their testosterone levels would be within the normal female range.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Not Measurable</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Individuals with M&uuml;llerian agenesis typically have ovaries that produce hormones, including measurable levels of testosterone within the female range.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Significantly Elevated (&gt;1000 ng/dL)</strong>: Significantly elevated testosterone levels are likely to be seen in conditions involving adrenal or ovarian tumors or other endocrine disorders.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In patients with M&uuml;llerian agenesis, a condition characterized by the congenital absence of the uterus and part of the vagina, hormone levels, including testosterone, are typically within the normal female range. This condition usually occurs in individuals with a 46,XX karyotype and normally functioning ovaries. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></p>",
    "correct_choice_id": 48297,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 12085,
    "choices": [
      {
        "id": 48304,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Streak gonads and male internal genitalia</span></span></span></span></p>"
      },
      {
        "id": 48305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Streak gonads and female internal genitalia</span></span></span></span></p>"
      },
      {
        "id": 48306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Empty pelvis (no gonads or internal genitalia)</span></span></span></span></p>"
      },
      {
        "id": 48307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral abdominal testes and male internal genitalia</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old nulligravida presents with primary amenorrhea. She is diagnosed with 46XY gonadal dysgenesis. During pelvic laparoscopy, what is the expected finding?</span></span></p>",
    "unique_key": "Q8387585",
    "question_audio": null,
    "question_video": null,
    "map_id": 12039,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans.&nbsp; B. Streak gonads and female internal genitalia</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The scenario described is 46 XY gonadal dysgenesis (or Swyer syndrome)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In Swyer syndrome, there will be normal female internal and external genitalia with the presence of male gonads which are non-functional</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The karyotype is 46XY</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us evaluate the expected findings during pelvic laparoscopy:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. Streak Gonads and Male Internal Genitalia</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This option would be more typical of complete androgen insensitivity syndrome (CAIS), where individuals with a 46XY karyotype develop female external genitalia but lack female internal genitalia due to the presence of testes that produce male levels of androgens.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Streak Gonads and Female Internal Genitalia</strong>: Correct. In 46XY gonadal dysgenesis, the individual typically has streak gonads (underdeveloped gonadal tissue) instead of fully developed testes or ovaries. Despite the 46XY karyotype, these individuals can have some form of female internal genitalia (like a uterus, although it may be underdeveloped). because the streak gonads do not produce the male hormones necessary to suppress female internal genitalia development. They are phenotypically female</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C. Empty Pelvis (No Gonads or Internal Genitalia)</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is less likely. While gonadal dysgenesis involves underdeveloped gonads (streak gonads), the presence of some internal genitalia is expected, especially in a case with a female phenotype.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Bilateral Abdominal Testes and Male Internal Genitalia</strong>: This scenario is more consistent with a condition like undescended testes in an individual with a male phenotype. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In patients with 46XY gonadal dysgenesis, pelvic laparoscopy typically reveals streak gonads and the presence of female internal genitalia. This condition involves underdeveloped gonadal tissue and the development of female internal genitalia due to the lack of male hormone production. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></span></span></p>",
    "correct_choice_id": 48305,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 12086,
    "choices": [
      {
        "id": 48308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadectomy due to increased risk of malignant transformation in retained gonads</span></span></span></span></p>"
      },
      {
        "id": 48309,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oophoropexy due to increased rate of torsion</span></span></span></span></p>"
      },
      {
        "id": 48310,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis ablation due to increased rate of endometriosis</span></span></span></span></p>"
      },
      {
        "id": 48311,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To see if fertility is possible</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old female is diagnosed with gonadal dysgenesis, and her karyotype reveals 45, X/46, XY mosaicism. Laparoscopy is performed for which of the following reasons?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture7_D11zrBu.jpg\" style=\"height:353px; width:250px\" /></span></span></p>",
    "unique_key": "Q4279196",
    "question_audio": null,
    "question_video": null,
    "map_id": 12040,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Gonadectomy due to increased risk of malignant transformation in retained gonads</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Whenever there is a 46XY karyotype in primary amenorrhoea, there is a strong likelihood of malignant transformation in the gonads</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hence gonadectomy should be done as soon as possible (In complete AIS, gonadectomy can be delayed till after puberty is complete)</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Gonadectomy due to Increased Risk of Malignant Transformation in Retained Gonads</strong>: Correct. Individuals with 45X/46XY mosaicism have an increased risk of gonadal malignancy, especially in the presence of Y chromosome material. Gonadectomy is recommended to reduce this risk, as the dysgenetic gonads in such cases are prone to developing gonadoblastoma and other germ cell tumors.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Oophoropexy due to Increased Rate of Torsion</strong>: Oophoropexy is a surgical procedure to fix the ovaries in place, typically performed to prevent torsion. However, this is not the primary concern in patients with 45, X/46, XY mosaicism, where the risk of malignancy is the more pressing issue.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Endometriosis Ablation due to Increased Rate of Endometriosis</strong>: There is no direct correlation between gonadal dysgenesis with 45, X/46, XY mosaicism and an increased rate of endometriosis. Endometriosis ablation would not be the primary indication for laparoscopy in this scenario.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>To See if Fertility is Possible</strong>: While assessing fertility potential is important, the immediate concern in a patient with 45, X/46, XY mosaicism is the risk of malignant transformation in the gonads. The primary reason for laparoscopy in this case is to perform a gonadectomy, if indicated.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In patients with gonadal dysgenesis and a 45, X/46, XY karyotype, laparoscopy and gonadectomy are recommended due to the increased risk of malignant transformation in retained gonads. This pre-emptive surgical approach is crucial to reduce the risk of gonadal malignancies in these patients</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></p>",
    "correct_choice_id": 48308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12089,
    "choices": [
      {
        "id": 48320,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-releasing hormone (GnRH) neurons fail to develop.</span></span></span></span></p>"
      },
      {
        "id": 48321,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a condition that leads to hypergonadotropic hypogonadism.</span></span></span></span></p>"
      },
      {
        "id": 48322,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intact sense of smell differentiates it from other similar conditions.</span></span></span></span></p>"
      },
      {
        "id": 48323,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can be inherited as an autosomal dominant or autosomal recessive disorder</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true of Kallmann syndrome? </span></span></p>",
    "unique_key": "Q6298291",
    "question_audio": null,
    "question_video": null,
    "map_id": 12043,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Can be inherited as an autosomal dominant or autosomal recessive disorder</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defects in the ability to smell (hyposmia or anosmia) and primary amenorrhoea is known as Kallmann syndrome. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is syndrome can be inherited as an X-linked, autosomal dominant, or autosomal recessive disorder </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kallmann patients have a normal complement of GnRH neurons, however, these neurons fail to migrate and instead remain near the nasal epithelium </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As a result, locally secreted GnRH is unable to stimulate gonadotrophs in the anterior pituitary gland to release LH and FSH. In turn, marked decreases in ovarian estrogen production result in absence of breast development and menstrual cycles.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kallmann syndrome is also associated with midline facial anomalies such as cleft palate, unilateral renal agenesis, cerebellar ataxia, epilepsy, neurosensory hearing loss, and synkinesis (mirror movements of the hands) </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There will be hypogonadotropic hypogonadism</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Gonadotropin-Releasing Hormone (GnRH) Neurons Fail to Develop</strong>: This statement is incorrect as in Kallmann syndrome.&nbsp; GnRH neurons fail to migrate properly during embryonic development, leading to a deficiency in GnRH. This deficiency impairs the normal function of the hypothalamic-pituitary-gonadal axis, causing hypogonadotropic hypogonadism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>It is a condition that leads to Hypergonadotropic Hypogonadism</strong>: Incorrect. Kallmann syndrome leads to hypogonadotropic hypogonadism. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Intact Sense of Smell Differentiates it from Other Similar Conditions</strong>: Incorrect. In Kallmann syndrome, the sense of smell is typically impaired (anosmia or hyposmia). This feature distinguishes it from other forms of hypogonadotropic hypogonadism where the sense of smell is intact.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Can be Inherited as an Autosomal Dominant or Autosomal Recessive Disorder</strong>: Kallmann syndrome can be inherited in multiple patterns, including autosomal dominant, autosomal recessive, and X-linked forms. The genetic heterogeneity of this condition allows for different inheritance patterns.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Kallmann syndrome is characterized by hypogonadotropic hypogonadism and an impaired sense of smell (anosmia or hyposmia). It can be inherited in an autosomal dominant, autosomal recessive, or X-linked pattern. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></span></strong></span></span></p>",
    "correct_choice_id": 48323,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 12092,
    "choices": [
      {
        "id": 48332,
        "text": "<p><span style=\"font-size:16px;\">Serum&nbsp;</span><span style=\"font-size:12.0pt;\">Luteinizing hormone (LH)</span></p>"
      },
      {
        "id": 48333,
        "text": "<p><span style=\"font-size:16px;\">Serum&nbsp;</span><span style=\"font-size:12.0pt;\">Follicle-stimulating hormone (FSH)</span></p>"
      },
      {
        "id": 48334,
        "text": "<p><span style=\"font-size:12.0pt;\">Urine Human chorionic gonadotropin (hCG)</span></p>"
      },
      {
        "id": 48335,
        "text": "<p><span style=\"font-size:16px;\">Serum&nbsp;</span><span style=\"font-size:12.0pt;\">Thyroid-stimulating hormone (TSH)</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 15-year-old with primary amenorrhea and Tanner stage V breast development presents for evaluation.&nbsp; Assessing levels for which of the following is the appropriate next step in her evaluation?</span></p>",
    "unique_key": "Q5139838",
    "question_audio": null,
    "question_video": null,
    "map_id": 12046,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ans. C. Urine Human chorionic gonadotropin (hCG)</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><span style=\"font-size:16px;\">As secondary sexual characters are present, the ovaries are functional</span></li><li><span style=\"background-color:transparent;font-size:16px;\">Although this is labeled primary amenorrhea, ovulation may occur before the first recognized menstruation \u2014 making pregnancy possible.</span></li><li><span style=\"font-size:16px;\">The first thing that needs to be ruled out (even though she has primary amenorrhoea) in such a situation is pregnancy</span></li><li><span style=\"font-size:16px;\">Hence hCG is the next best step in her evaluation</span></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Let us consider each option</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;A.</strong>&nbsp;<strong>Serum Luteinizing Hormone (LH)</strong>: LH is involved in the regulation of the menstrual cycle and ovulation. While it can be useful in evaluating amenorrhea, it is not the first test to consider in a sexually active adolescent with primary amenorrhea.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;B</strong>.&nbsp;<strong>Serum&nbsp;Follicle-Stimulating Hormone (FSH)</strong>: FSH stimulates the growth of ovarian follicles. High levels can indicate ovarian failure, while low levels can suggest a pituitary or hypothalamic problem. However, like LH, it's not the initial test in this context.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;C.</strong>&nbsp;<strong>Urine Human Chorionic Gonadotropin (hCG)</strong>: Correct. The first step in the evaluation of a sexually active adolescent with primary amenorrhea is to rule out pregnancy. An hCG test, which detects pregnancy, is the most appropriate initial test, even in the presence of primary amenorrhea.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option&nbsp;D</strong>.&nbsp;<strong>Serum&nbsp;Thyroid-Stimulating Hormone (TSH)</strong>: TSH regulates thyroid function, which can impact menstrual cycles. However, thyroid dysfunction is less likely the cause in a patient with primary amenorrhea and normal development of secondary sexual characteristics.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Educational Objective</strong>: In a sexually active adolescent with primary amenorrhea and normal secondary sexual development, the first step is to rule out pregnancy with an hCG test. Pregnancy is a common and potentially reversible cause of amenorrhea, and its confirmation or exclusion guides further evaluation and management</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ref:&nbsp;Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48334,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 12095,
    "choices": [
      {
        "id": 48344,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PCOS</span></span></span></span></p>"
      },
      {
        "id": 48345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis</span></span></span></span></p>"
      },
      {
        "id": 48346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperprolactinemia</span></span></span></span></p>"
      },
      {
        "id": 48347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian androgen-producing tumour</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Of the following conditions, which is most likely associated with the following finding?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture8_hSUrKHc.jpg\" style=\"height:365px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q2351493",
    "question_audio": null,
    "question_video": null,
    "map_id": 12047,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Ovarian androgen-producing tumour</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is an image showing clitoromegaly (Clitoris &gt; 1 cm)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a sign of virilization</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical Features of Virilization are</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Acne </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgenic alopecia </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirsutism </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased breast size </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amenorrhea </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deepening of the voice </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clitoromegaly </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased muscle mass</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Virilization reflects higher androgen levels and should prompt investigation for an androgen-producing tumour of the ovary or adrenal gland</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us explore each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>A.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>PCOS (Polycystic Ovary Syndrome)</strong>: PCOS is characterized by a combination of symptoms like irregular menstrual cycles, polycystic ovaries, and signs of hyperandrogenism (e.g., hirsutism, acne). </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Endometriosis</strong>: Endometriosis involves the growth of endometrial tissue outside the uterus, causing pelvic pain, especially during menstruation, and may lead to infertility. It is not typically associated with findings indicative of an acute androgen increase.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hyperprolactinemia</strong>: Hyperprolactinemia can lead to symptoms like galactorrhea (milk production), amenorrhea, and infertility. It doesn&rsquo;t generally produce findings suggestive of excessive androgen production.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></span></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Ovarian Androgen-Producing Tumour</strong>: Correct. Ovarian androgen-producing tumors, such as Sertoli-Leydig cell tumors, can cause significantly elevated levels of androgens, leading to symptoms like hirsutism, virilization, and menstrual irregularities. This would be consistent with a finding indicative of high androgen levels.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Ovarian androgen-producing tumors can lead to markedly elevated androgen levels, resulting in signs of virilization and hirsutism. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 420, Williams Gynecology 3<sup>rd</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48347,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 12097,
    "choices": [
      {
        "id": 48352,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A, B, C, D, E</span></span></p>"
      },
      {
        "id": 48353,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A, B, C, D</span></span></p>"
      },
      {
        "id": 48354,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A, B</span></span></p>"
      },
      {
        "id": 48355,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A,B,D</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year female presents to OPD with secondary amenorrhea. She does not bleed on the progesterone challenge or even after giving her a course of combined estrogen and progesterone pills. Asherman syndrome is suspected. This can result from. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Curettage</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculosis </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Uterine artery embolization</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cesareans section</span></span></li>\r\n\t<li><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical biopsy</span></span></li>\r\n</ol>",
    "unique_key": "Q7339584",
    "question_audio": null,
    "question_video": null,
    "map_id": 18811,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. A, B, C, D</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option :</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Curettage</span></strong>: Asherman syndrome is often a result of trauma to the uterine lining, most commonly due to aggressive curettage, especially postpartum or post-abortion curettage.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tuberculosis</span></strong>: Genital tuberculosis, particularly uterine tuberculosis, can lead to the development of intrauterine adhesions, contributing to Asherman syndrome.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine Artery Embolization</span></strong>: Uterine artery embolization, typically used to treat uterine fibroids, can cause damage to the endometrium and lead to the formation of intrauterine adhesions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cesarean Section</span></strong>: Though less common, Asherman syndrome can occur post-cesarean section if there is endometrial damage during the surgery, leading to scar formation.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. E.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical Biopsy</span></strong>: A cervical biopsy is less likely to cause intrauterine scarring compared to the procedures listed in the other options.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most comprehensive and accurate answer for the causes of Asherman syndrome in the given options would be <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. A, B, C, D</span></strong>, which encompasses curettage, tuberculosis, uterine artery embolization, and cesarean section.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asherman syndrome is typically caused by intrauterine trauma or surgery (like curettage or uterine artery embolization), certain infections (like genital tuberculosis), and less commonly by cesarean sections. Understanding these causes is essential for preventing and managing Asherman syndrome, which can lead to secondary amenorrhea and infertility</span></span></span></p>\r\n\r\n<p style=\"margin-left:68px; text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Asherman syndrome is intrauterine adhesions or synechiae</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">They arise due to</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Surgical trauma to the uterus which may be seen following</span></span>\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dilatation and curettage (esp sharp curettage)</span></span></li>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cesarean section</span></span></li>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Myomectomy where the endometrial cavity is involved</span></span></li>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Metroplasty</span></span></li>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Trans-cervical resection of the endometrium</span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Uterine artery embolization</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Endometrial ablative procedures </span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intra-uterine infections like tuberculosis and schistosomiasis</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">But the classical history is usually after a D &amp; C, the patient develops amenorrhoea</span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Symptoms:</span></span>\r\n\r\n\t<ul style=\"list-style-type:disc\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hypomenorrhea</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary amenorrhoea </span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary infertility</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diagnosis</span></span>\r\n\t<ul style=\"list-style-type:disc\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">On ultrasound:</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Uterine cavity appears irregular/ interrupted; punctate echogenic foci in the endometrium/ indistinct endo-myometrial junction/ endometrial fluid: commonly loculated appearing as small focal cystic areas within the endometrium</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">On HSG</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intra-uterine filling defects are seen giving a moth-eaten appearance</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hysteroscopy</span></span>\r\n\t\t<ul>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#3d3d3d\">Gold standard for diagnosis</span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#3d3d3d\">Treatment:</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#3d3d3d\">Hysteroscopic adhesiolysis</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:black\">Post procedure:</span></span></span>\r\n\t\t<ul style=\"list-style-type:square\">\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:black\">&nbsp;To stimulate endometrial proliferation and prevent reformation of adhesions, oral oestrogen administration has proved effective. A cooper containing intra-uterine device can also be inserted to prevent reformation of adhesions</span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:black\">Another hysteroscopy or HSG is typically performed at 3 months following the initial resection. </span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#3d3d3d\">Ref: Page 1080, William&rsquo;s gynecology, 3<sup>rd</sup> edition</span></span></span></strong></p>",
    "correct_choice_id": 48353,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12099,
    "choices": [
      {
        "id": 48360,
        "text": "<p><span style=\"font-size:12pt;\">PCOS</span></p>"
      },
      {
        "id": 48361,
        "text": "<p><span style=\"font-size:12pt;\">Asherman syndrome</span></p>"
      },
      {
        "id": 48362,
        "text": "<p><span style=\"font-size:12pt;\">Cervical stenosis</span></p>"
      },
      {
        "id": 48363,
        "text": "<p><span style=\"font-size:12pt;\">Gonadal dysgenesis</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 30-year-old female presents to OPD with secondary amenorrhea for 2 years. She has 2 living issues and has undergone two surgical abortions in the past Her BMI is 30 kg/m2. She has no withdrawal bleeding after progesterone or after estrogen and progesterone. The likely cause is:</span></p>",
    "unique_key": "Q4647856",
    "question_audio": null,
    "question_video": null,
    "map_id": 18812,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B. Asherman syndrome</strong></span></p><p style=\"margin-left:48px;text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Let us look at the other options:</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. A.</strong>&nbsp;<strong>Polycystic Ovary Syndrome (PCOS)</strong>: PCOS is characterized by irregular menstrual cycles, signs of hyperandrogenism (such as hirsutism or acne), and polycystic ovaries on ultrasound. However, women with PCOS typically have some bleeding in response to progesterone due to built-up endometrial lining, making this answer less likely</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. C.</strong>&nbsp;<strong>Cervical Stenosis</strong>: Cervical stenosis refers to the narrowing of the cervical canal. It can cause amenorrhea by physically blocking the passage of menstrual blood. However, in cervical stenosis, the endometrium typically responds to hormonal stimulation and there may be some evidence of trapped blood or hematometra on imaging, distinguishing it from Asherman syndrome.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. D.</strong>&nbsp;<strong>Gonadal Dysgenesis</strong>: Gonadal dysgenesis, such as Turner syndrome or Swyer syndrome, typically presents with primary amenorrhea and underdeveloped secondary sexual characteristics, not secondary amenorrhea.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Asherman syndrome, characterized by the formation of intrauterine adhesions or scars, typically presents with secondary amenorrhea and a lack of withdrawal bleeding after hormonal challenges. It is often a result of uterine surgery or trauma.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>About Asherman Syndrome:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The diagnosis of Asherman syndrome is based primarily on a high index of suspicion, based on history. In women whose history suggests this possibility, scant or no withdrawal bleeding after sequential treatment with exogenous estrogen and progestin reflects end-organ endometrial failure and corroborates the clinical suspicion.</span></p></li><li><span style=\"font-size:12pt;\">Asherman syndrome is intra uterine adhesions.</span></li><li><span style=\"font-size:12pt;\">They arise due to:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Surgical trauma to the uterus which may be seen following</span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">Dilatation and curettage (esp sharp curettage)</span></li><li><span style=\"font-size:12pt;\">Cesarean section</span></li><li><span style=\"font-size:12pt;\">Myomectomy where the endometrial cavity is involved</span></li><li><span style=\"font-size:12pt;\">Metroplasty</span></li><li><span style=\"font-size:12pt;\">Trans-cervical resection of the endometrium</span></li></ul></li><li><span style=\"font-size:12pt;\">Uterine artery embolization</span></li><li><span style=\"font-size:12pt;\">Endometrial ablative procedures</span></li><li><span style=\"font-size:12pt;\">Intra-uterine infections like tuberculosis and schistosomiasis</span></li></ul></li><li><span style=\"font-size:12pt;\">Symptoms:</span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12pt;\">Hypomenorrhea</span></li><li><span style=\"font-size:12pt;\">Secondary amenorrhoea</span></li><li><span style=\"font-size:12pt;\">Secondary infertility</span></li></ul></li><li><span style=\"font-size:12pt;\">Diagnosis</span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12pt;\">On ultrasound</span></li></ul></li><li><span style=\"font-size:12pt;\">Uterine cavity appears irregular/ interrupted; punctate echogenic foci in the endometrium/ indistinct endo-myometrial junction/ endometrial fluid: commonly loculated appearing as small focal cystic areas within the endometrium</span></li><li><span style=\"font-size:12pt;\">On HSG</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Intra-uterine filling defects are seen giving a moth-eaten appearance</span></li></ul></li><li><span style=\"font-size:12pt;\">Hysteroscopy</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Gold standard for diagnosis</span></li></ul></li><li><span style=\"font-size:12pt;\">Treatment:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Hysteroscopic adhesiolysis</span></li><li><span style=\"font-size:12pt;\">Post procedure:</span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">&nbsp;To stimulate endometrial proliferation and prevent reformation of adhesions, oral oestrogen administration has proved effective. A cooper containing intra-uterine device can also be inserted to prevent reformation of adhesions</span></li><li><span style=\"font-size:12pt;\">Another hysteroscopy or HSG is typically performed at 3 months following the initial resection.</span></li></ul></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48361,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12101,
    "choices": [
      {
        "id": 48368,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sheehan syndrome</span></span></p>"
      },
      {
        "id": 48369,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Asherman syndrome</span></span></p>"
      },
      {
        "id": 48370,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Premature ovarian insufficiency</span></span></p>"
      },
      {
        "id": 48371,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Polycystic Ovarian syndrome</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old P2L2 woman who has undergone a tubal ligation comes to the OPD with amenorrhea 2 years after her ligation. Her FSH is high. Which of the following is the likely diagnosis: </span></span></p>",
    "unique_key": "Q1917737",
    "question_audio": null,
    "question_video": null,
    "map_id": 18813,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Premature ovarian insufficiency</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Premature ovarian failure/ or premature ovarian insufficiency is hypergonadotropic hypogonadism and amenorrhea occurring before the age of 40 years. </span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sheehan syndrome and Asherman syndrome will not have raised FSH</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">PCOS will have reversed LH:FSH ratio, have other pointers for diagnosis of PCOS (like the hyperandrogenism or ultrasound morphology suggestive of PCOS)</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sheehan Syndrome</span></strong>: Sheehan syndrome is caused by pituitary gland damage due to severe blood loss and hypovolemic shock during or after childbirth. It typically presents with low levels of pituitary hormones, not elevated FSH. This condition would cause hypogonadotropic hypogonadism.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asherman Syndrome</span></strong>: Asherman syndrome is characterized by intrauterine adhesions or scarring and is often a result of uterine surgery. While it can cause amenorrhea, it does not typically result in elevated FSH levels, as the issue is structural rather than ovarian.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic Ovarian Syndrome (PCOS)</span></strong>: PCOS is characterized by irregular menstrual cycles, signs of hyperandrogenism, and polycystic ovaries. PCOS typically involves normal or low FSH levels and does not usually lead to primary ovarian failure.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Premature ovarian insufficiency (POI) is characterized by the loss of normal ovarian function before the age of 40, presenting as amenorrhea with elevated FSH levels, indicative of hypergonadotropic hypogonadism. It is important to consider POI in women under 40 presenting with amenorrhea and high FSH levels, as it has implications for fertility and overall health</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></strong></span></span></p>",
    "correct_choice_id": 48370,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12102,
    "choices": [
      {
        "id": 48372,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">OCP</span></span></p>"
      },
      {
        "id": 48373,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cabergoline</span></span></p>"
      },
      {
        "id": 48374,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dexamethasone</span></span></p>"
      },
      {
        "id": 48375,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Oxytocin</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman presents to OPD with complaint of secondary amenorrhea. On examination, there is galactorrhoea, and her prolactin levels are high. Urine pregnancy test is negative. Which of the following is treatment of choice for her: </span></span></span></p>",
    "unique_key": "Q4689067",
    "question_audio": null,
    "question_video": null,
    "map_id": 18814,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. Cabergoline</strong></span></span></p>\r\n\r\n<p style=\"margin-left:48px; text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">This is a scenario of hyperprolactinemia which commonly presents as galactorrhoea and oligomenorrhoea (Delayed cycles)</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dopamine agonists are the first line treatment for hyperprolactinemia. Bromocriptine and cabergoline are first line treatments. </span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral Contraceptive Pills (OCP)</span></strong>: OCPs are used to regulate menstrual cycles and provide contraception</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamethasone</span></strong>: is a steroid used in the treatment of various conditions, including some endocrine disorders, but it is not a first-line treatment for hyperprolactinemia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxytocin</span></strong>: Oxytocin is a hormone that stimulates uterine contractions and milk ejection in lactation</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The treatment of choice for hyperprolactinemia, which often presents with galactorrhoea and secondary amenorrhea, is dopamine agonists such as cabergoline or bromocriptine. These medications effectively lower prolactin levels, which can help restore normal menstrual function and resolve galactorrhoea</span></span></span></p>\r\n\r\n<p style=\"margin-left:24px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Speroff&rsquo;s 9<sup>th</sup> edition chapter 10, amenorrhea</span></strong></span></span></p>",
    "correct_choice_id": 48373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12104,
    "choices": [
      {
        "id": 48380,
        "text": "<p><span style=\"font-size:12pt;\">Asherman syndrome</span></p>"
      },
      {
        "id": 48381,
        "text": "<p><span style=\"font-size:12pt;\">Sheehan syndrome</span></p>"
      },
      {
        "id": 48382,
        "text": "<p><span style=\"font-size:12pt;\">PCOS</span></p>"
      },
      {
        "id": 48383,
        "text": "<p><span style=\"font-size:12pt;\">Primary ovarian insufficiency</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 30 y comes to OPD for evaluation of absent periods. The patient had a vaginal delivery 8 months ago and she\u2019s not had her period since delivery. Her postpartum course was complicated by atonic PPH requiring massive blood transfusion. At a visit, 2 months ago, the patient was started on combined OCPs, and she has not had vaginal bleeding. Prior to this pregnancy she had regular monthly cycles. She also has increased fatigue. She is not lactating and is bottle feeding her baby. There is no headache, galactorrhoea, or hot flushes. BMI is 31, vitals are normal. Pelvic examination shows clear vaginal discharge and well rugate vagina. The uterus is small and anteverted. UPT is negative. TSH levels are elevated. What is the most likely diagnosis?</span></p>",
    "unique_key": "Q4036944",
    "question_audio": null,
    "question_video": null,
    "map_id": 18815,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B. Sheehan Syndrome</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Etiopathogenesis:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">During pregnancy, the <strong>pituitary gland enlarges</strong> due to hyperplasia of lactotrophs.</span></li><li><span style=\"font-size:16px;\">In the setting of <strong>severe blood loss or hypotension</strong> during/after delivery, the <strong>enlarged pituitary is vulnerable to ischemia</strong>.</span></li><li><span style=\"font-size:16px;\">Leads to <strong>necrosis of pituitary tissue</strong>, resulting in <strong>partial or complete hypopituitarism</strong>.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Clinical Features:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Early signs:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Failure to lactate (due to \u2193 prolactin)</span></li><li><span style=\"font-size:16px;\">Prolonged amenorrhea or oligomenorrhea</span></li><li><span style=\"font-size:16px;\">Fatigue, hypotension</span></li></ul></li><li><span style=\"font-size:16px;\"><strong>Late signs:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Loss of secondary sexual hair (pubic/axillary)</span></li><li><span style=\"font-size:16px;\">Cold intolerance, dry skin (\u2193 TSH)</span></li><li><span style=\"font-size:16px;\">Hypoglycemia, weight loss (\u2193 ACTH, cortisol)</span></li><li><span style=\"font-size:16px;\">Infertility</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Diagnosis:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">History of <strong>severe PPH</strong> with failure to resume normal postpartum function</span></li><li><span style=\"font-size:16px;\">Hormonal assays: \u2193 levels of <strong>prolactin, ACTH, TSH, LH, FSH, GH</strong></span></li><li><span style=\"font-size:16px;\"><strong>MRI of pituitary</strong> may show an empty sella or hypoplastic gland</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Treatment:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Lifelong hormone replacement therapy</strong>, including:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\"><strong>Glucocorticoids</strong> (hydrocortisone)</span></li><li><span style=\"font-size:16px;\"><strong>Levothyroxine</strong></span></li><li><span style=\"font-size:16px;\"><strong>Estrogen/progesterone</strong> (if fertility not desired)</span></li><li><span style=\"font-size:16px;\"><strong>Gonadotropins</strong> (if fertility desired)</span></li></ul></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Let us look at the other options:</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A.</strong> <strong>Asherman syndrome</strong>: Asherman syndrom<strong>e</strong> is a condition characterized by intrauterine adhesions or synechiae, often resulting from trauma to the endometrium, typically after dilation and curettage. It leads to menstrual abnormalities (amenorrhea or hypomenorrhea), infertility, and recurrent pregnancy loss. Diagnosis is confirmed by hysteroscopy, and treatment involves surgical adhesiolysis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option. C.</strong>&nbsp;<strong>Polycystic Ovary Syndrome (PCOS)</strong>: PCOS is an endocrine disorder characterized by irregular menstrual cycles, signs of hyperandrogenism, and polycystic ovaries. While the patient has an elevated BMI, a common feature in PCOS, the absence of her periods following a complicated postpartum course and the absence of typical PCOS symptoms make this diagnosis less likely.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option. D.</strong>&nbsp;<strong>Primary Ovarian Insufficiency</strong>: Primary ovarian insufficiency, also known as premature ovarian failure, involves early depletion of ovarian follicles and usually presents with elevated FSH levels, which is not the case here.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Asherman syndrome, characterized by intrauterine adhesions or scarring typically following uterine surgery or trauma, is the most likely cause of secondary amenorrhea in a patient with a history of postpartum hemorrhage and D&amp;C. The diagnosis is supported by the absence of menstrual bleeding even with hormonal stimulation and a history suggestive of intrauterine injury.</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><span style=\"font-size:16px;\">Asherman syndrome is intra uterine adhesions, they arise due to:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Surgical trauma to the uterus which may be seen following</span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:16px;\">Dilatation and curettage (esp. sharp curettage)</span></li><li><span style=\"font-size:16px;\">Cesarean section</span></li><li><span style=\"font-size:16px;\">Myomectomy where the endometrial cavity is involved</span></li><li><span style=\"font-size:16px;\">Metroplasty</span></li><li><span style=\"font-size:16px;\">Trans-cervical resection of the endometrium</span></li></ul></li><li><span style=\"font-size:16px;\">Uterine artery embolization</span></li><li><span style=\"font-size:16px;\">Endometrial ablative procedures</span></li><li><span style=\"font-size:16px;\">Intra-uterine infections like tuberculosis and schistosomiasis</span></li></ul></li><li><span style=\"font-size:16px;\">Symptoms:</span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">Hypomenorrhea</span></li><li><span style=\"font-size:16px;\">Secondary amenorrhoea</span></li><li><span style=\"font-size:16px;\">Secondary infertility</span></li></ul></li><li><span style=\"font-size:16px;\">Diagnosis</span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">On ultrasound</span></li></ul></li><li><span style=\"font-size:16px;\">Uterine cavity appears irregular/ interrupted; punctate echogenic foci in the endometrium/ indistinct endo-myometrial junction/ endometrial fluid: commonly loculated appearing as small focal cystic areas within the endometrium</span></li><li><span style=\"font-size:16px;\">On HSG</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Intra-uterine filling defects are seen giving a moth-eaten appearance</span></li></ul></li><li><span style=\"font-size:16px;\">Hysteroscopy</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Gold standard for diagnosis</span></li></ul></li><li><span style=\"font-size:16px;\">Treatment:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\">Hysteroscopic adhesiolysis</span></li><li><span style=\"font-size:16px;\">Post procedure:</span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:16px;\">&nbsp;To stimulate endometrial proliferation and prevent reformation of adhesions, oral estrogen administration has proved effective. A cooper containing intra-uterine device can also be inserted to prevent reformation of adhesions</span></li><li><span style=\"font-size:16px;\">Another hysteroscopy or HSG is typically performed at 3 months following the initial resection.</span></li></ul></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Ref: Speroff\u2019s 9<sup>th</sup> edition chapter 10, amenorrhea</strong></span></p>",
    "correct_choice_id": 48381,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 12106,
    "choices": [
      {
        "id": 48388,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Elevated luteinizing hormone (LH) level</span></span></p>"
      },
      {
        "id": 48389,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Elevated gonadotropin-releasing hormone (GnRH) level</span></span></p>"
      },
      {
        "id": 48390,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Elevated leptin level</span></span></p>"
      },
      {
        "id": 48391,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Elevated neuropeptide Y level</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old with previously regular menses, presents with amenorrhea. She is also diagnosed with anorexia nervosa. Which of the following is likely to be seen in this patient?</span></span></p>",
    "unique_key": "Q8081570",
    "question_audio": null,
    "question_video": null,
    "map_id": 18816,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Elevated neuropeptide Y level</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In anorexia nervosa, there is Hypogonadotrophic hypogonadism</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The FSH, LH levels are reduced and so are the estrogen levels</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Various biologic actors have been implicated in eating disorder development</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Abnormalities in neuropeptides, neurotransmitters, and hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes are reported </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patients with anorexia nervosa have been found to have low circulating leptin levels</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It has been hypothesized that a decrease in leptin production due to weight loss could secondarily stimulate neuropeptide Y, which is known to stimulate hunger and alter GnRH pulsatility.</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option. A.</strong>&nbsp;<strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated Luteinizing Hormone (LH) Level</span></strong>: Incorrect. In anorexia nervosa, there is typically hypogonadotropic hypogonadism, characterized by low levels of gonadotropins, including LH. This is due to the body&#39;s response to starvation and undernutrition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated Gonadotropin-Releasing Hormone (GnRH) Level</span></strong>: Incorrect. GnRH levels are often reduced in anorexia </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated Leptin Level</span></strong>: Incorrect. Leptin, a hormone produced by adipose tissue, is typically low in anorexia nervosa due to the loss of body fat. Low leptin levels are associated with reduced energy intake and weight loss.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated Neuropeptide Y Level</span></strong>: Correct. Neuropeptide Y is involved in the regulation of appetite and is known to stimulate hunger. In anorexia nervosa, the decrease in leptin due to weight loss can lead to an increase in neuropeptide Y as a compensatory mechanism to stimulate appetite. Additionally, neuropeptide Y can alter GnRH pulsatility, contributing to menstrual irregularities.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In anorexia nervosa, there is typically hypogonadotropic hypogonadism with reduced levels of LH, FSH, and estrogen. Low circulating leptin levels due to weight loss can stimulate neuropeptide Y, which affects appetite regulation and GnRH pulsatility. This hormonal dysregulation contributes to the development of amenorrhea in patients with anorexia nervosa.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 404, Williams Gynecology 3<sup>rd</sup> edition</span></span></strong></p>",
    "correct_choice_id": 48391,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 12109,
    "choices": [
      {
        "id": 48400,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patients typically present with amenorrhea. </span></span></p>"
      },
      {
        "id": 48401,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is the most common cause of chronic anovulation. </span></span></p>"
      },
      {
        "id": 48402,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is characterized by hypogonadotropic hypogonadism.</span></span></p>"
      },
      {
        "id": 48403,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">It is characterized by persistently elevated follicle stimulating hormone (FSH) and oestradiol levels</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true regarding polycystic ovarian syndrome?</span></span></p>",
    "unique_key": "Q1043930",
    "question_audio": null,
    "question_video": null,
    "map_id": 18817,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. It is the most common cause of chronic anovulation. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PCOS</span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">This is syndrome is by far the most common cause of chronic anovulation</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Women with PCOS have different menstrual patterns</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Amenorrhoea due to anovulation</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Heavy menstrual bleeding and intermenstrual bleeding can result from unopposed estrogen stimulation of the endometrium</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In PCOS</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">LH &gt; FSH</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Oestradiol levels are usually normal</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"margin-left:96px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Let&#39;s evaluate each statement regarding polycystic ovarian syndrome (PCOS):</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients typically present with amenorrhea</span></strong>: While amenorrhea can occur in PCOS, it&#39;s more common for patients to present with irregular menstrual cycles or oligomenorrhea rather than complete absence of menstruation. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is the most common cause of chronic anovulation</span></strong>: Correct. This chronic anovulation contributes to irregular menstrual cycles and infertility, both hallmark symptoms of PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is characterized by hypogonadotropic hypogonadism</span></strong>: This is incorrect. PCOS is actually characterized by hyperandrogenism (excess male hormones) and is not typically associated with hypogonadotropic hypogonadism. In fact, women with PCOS often have normal or slightly elevated levels of gonadotropins like LH.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is characterized by persistently elevated follicle stimulating hormone (FSH) and oestradiol levels</span></strong>: This statement is not accurate for PCOS. In PCOS, FSH levels are usually normal or slightly lower, not persistently elevated. The hormonal hallmark of PCOS is an elevated LH to FSH ratio, along with elevated levels of androgens.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Educational Objective</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">: Polycystic ovarian syndrome (PCOS) is the most common cause of chronic anovulation and is characterized by symptoms such as irregular menstrual cycles, hyperandrogenism, and polycystic ovaries. Understanding PCOS&#39;s clinical presentation and hormonal profile is essential for diagnosis and management.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 406, Williams Gynecology 3<sup>rd</sup> edition</span></span></strong></p>",
    "correct_choice_id": 48401,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12112,
    "choices": [
      {
        "id": 48412,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Adrenal hyperplasiaI</span></p>"
      },
      {
        "id": 48413,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Idiopathic hirsutism</span></p>"
      },
      {
        "id": 48414,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic Ovarian Syndrome</span></p>"
      },
      {
        "id": 48415,
        "text": "<p><span style=\"font-size:12.0pt;\">Testosterone secreting tumor</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 20-year-old girl presents to the OPD with excess facial hair for 6 months and delayed menstrual cycles. On evaluation, levels of free testosterone are increased. An ultrasound reveals normal uterus and normal ovaries on USG. The most likely diagnosis is?</span></p>",
    "unique_key": "Q1275961",
    "question_audio": null,
    "question_video": null,
    "map_id": 18819,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. C. Polycystic Ovarian Syndrome</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic ovarian syndrome/ disease (PCOS/PCOD) is a disorder of chronically abnormal ovarian function (oligo/anovulation) and hyperandrogenism frequently associated with hyperinsulinemia and insulin resistance, resulting in menstrual irregularity, infertility, and hirsutism.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Rotterdam 2003 criteria is used to diagnose&nbsp; PCOS/PCOD:&nbsp;As per this criterion, at least 2 of 3 should be present:</strong></span></p><ol style=\"list-style-type:decimal;\"><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Oligo/anovulation (causes oligomenorrhea, 20<sup> </sup>amenorrhea, and infertility)</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Hyperandrogenism: Biochemical or clinical (increased serum androgens or acne, hirsutism)</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>12 or more than 12 follicle 2-9 mm in size present within 1 or both ovaries on USG and/or ovarian volume &gt; 10 mL (pearl necklace pattern).</strong></span></p></li></ol></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture9_0mgVKz8.jpg\" alt=\"\" width=\"300\" height=\"204\"></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">USG appearance of polycystic ovaries</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">As the patient in the question satisfies first 2 criteria, she is a case of PCOS</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>let's consider the other options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Adrenal Hyperplasia</strong>: Adrenal hyperplasia, particularly congenital adrenal hyperplasia (CAH), can cause symptoms similar to PCOS, including hirsutism and menstrual irregularities, due to elevated androgens. However, it is usually diagnosed earlier in life and often has other associated adrenal hormone abnormalities.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Idiopathic Hirsutism</strong>: Idiopathic hirsutism refers to hirsutism (excess hair growth) in the absence of any identifiable hormonal imbalance or ovarian/adrenal gland disorder. Given the increased free testosterone levels in this patient, idiopathic hirsutism is less likely.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Testosterone Secreting Tumor</strong>: While a testosterone-secreting tumor can cause increased androgen levels and symptoms like hirsutism, these tumors are rare. The more common presentation of such tumors would include rapid onset of symptoms and <strong>markedly elevated testosterone levels.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic Ovarian Syndrome (PCOS) is the most likely diagnosis in a young woman presenting with hirsutism, menstrual irregularities, and elevated free testosterone levels. The diagnosis of PCOS is based on a combination of clinical, biochemical, and ultrasound findings, and it is important to consider this condition in women with such symptoms.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 401, Speroff\u2019s Clinical Gynaecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48414,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12113,
    "choices": [
      {
        "id": 48416,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">a, b, c</span></p>"
      },
      {
        "id": 48417,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">b, d, e</span></p>"
      },
      {
        "id": 48418,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">a, b, e</span></p>"
      },
      {
        "id": 48419,
        "text": "<p><span style=\"font-size:12.0pt;\">b, c, d</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following is correct about polycystic ovarian disease (PCOD)?</span></p><p style=\"text-align:justify;\">&nbsp;</p><ol style=\"list-style-type:lower-alpha;\"><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Testosterone&gt; 2 ng/ml</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Infertility</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">High FSH/LH ratio</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Fasting glucose/ insulin ratio &gt; 4.5</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic appearance on 1 or both ovaries on ultrasound</span></p></li></ol>",
    "unique_key": "Q9724069",
    "question_audio": null,
    "question_video": null,
    "map_id": 18820,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. B. b, d, e</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">PCOS includes chronic non ovulation, hyperandrogenism associated with normal or raised estradiol level (E2), raised LH0 &amp; low FSH/LH ratio.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Diagnosis:&nbsp;</strong>Diagnosis is based upon the presence of any two of the following three criteria (Rotterdam Criteria)</span></p><ol style=\"list-style-type:decimal;\"><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Oligomenorrhoea/or anovulation (Delayed cycles and infertility)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Hyperandrogenism (Clinical &amp;/or biochemical)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic ovaries (Ultrasound finding of 1 OR both ovaries)</span></p></li></ol></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">On investigations,&nbsp;</span></p><ul style=\"list-style-type:circle;\"><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">LH: FSH ratio is increased (3:1) i.e. LH is more than FSH</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Increase free testosterone levels</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Increase DHEAS</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Fasting glucose: insulin ratio &lt; 4.5</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Sex hormone binding globulin decreases</span></p></li></ul></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Possible late sequelae of PCOD are:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Risk of developing diabetes mellitus (15%) due to insulin resistance</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Risk of developing endometrial carcinoma due to elevated level of estrogen.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Risk of hypertension &amp; cardiovascular disease due w abnormal lipid profile (dyslipidaemia)</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let us look at each option</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. A.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Testosterone &gt; 2 ng/ml</strong>: Elevated testosterone levels are a hallmark of PCOS, reflecting the condition's hyperandrogenic state. However, a level &gt; 2 ng/ml is quite high and not a typical threshold for PCOS diagnosis. Elevated testosterone in PCOS is usually more modest.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. B.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Infertility</strong>: Correct. Infertility is a common complication of PCOS due to chronic anovulation (lack of ovulation). Many women with PCOS struggle with infertility or subfertility.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>High FSH/LH Ratio</strong>: This is incorrect. In PCOS, the LH to FSH ratio is often elevated (reversed), not the FSH to LH ratio. A common finding is an LH to FSH ratio greater than 2:1.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. D.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Fasting Glucose/Insulin Ratio &gt; 4.5</strong>: Correct. &nbsp;While insulin resistance is a feature of PCOS, this specific ratio is not a standard diagnostic criterion for the condition. PCOS is often associated with insulin resistance, but diagnostic criteria typically don't include a specific fasting glucose/insulin ratio.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option E.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Polycystic Appearance on 1 or Both Ovaries on Ultrasound</strong>: Correct. One of the diagnostic criteria for PCOS, according to the Rotterdam criteria, is the presence of polycystic ovaries on ultrasound, characterized by 12 or more follicles measuring 2-9 mm in diameter, or an increased ovarian volume (&gt;10 cm\u00b3) in one or both ovaries.</span></p><p style=\"text-align:justify;\"><br><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic ovarian disease (PCOD/PCOS) is characterized by features such as hyperandrogenism (e.g., elevated testosterone levels), infertility due to chronic anovulation, and polycystic ovaries on ultrasound. Understanding these features is key in the diagnosis and management of PCOS.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 411, Speroff\u2019s clinical gynaecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48417,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 12115,
    "choices": [
      {
        "id": 48424,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Marked elevation of LH in contrast to FSH</span></span></span></span></p>"
      },
      {
        "id": 48425,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin resistance</span></span></span></span></p>"
      },
      {
        "id": 48426,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevation of plasma testosterone</span></span></span></span></p>"
      },
      {
        "id": 48427,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevation in the levels of sex hormone binding globulin (SHBG)</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The biochemical chaanges in established cases of Stein-Leventhal syndrome are all except?</span></span></p>",
    "unique_key": "Q8938157",
    "question_audio": null,
    "question_video": null,
    "map_id": 18821,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Elevation in the levels of sex hormone binding globulin (SHBG)</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stein Leventhal syndrome is the older name of PCOS</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In PCOS (Stein Leventhal syndrome) the levels of SHBG decrease</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other features of PCOS are</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LH: FSH ratio is increased (3:1) i.e. LH is more than FSH</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase free testosterone levels. </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase DHEAS</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasting glucose: insulin ratio &lt; 4.5</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sex hormone binding globulin decreases.</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s examine each statement:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Marked elevation of LH in contrast to FSH</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. In PCOS, there is often a marked elevation of LH relative to FSH, leading to an increased LH:FSH ratio. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin Resistance</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. Insulin resistance is a common finding in PCOS, contributing to its pathophysiology. It is associated with an increased risk of type 2 diabetes and other metabolic complications in these patients.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Elevation of Plasma Testosterone</strong>: Correct. Hyperandrogenism, characterized by elevated levels of testosterone, is a hallmark of PCOS. This leads to symptoms such as hirsutism, acne, and androgenic alopecia.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevation in the Levels of Sex Hormone Binding Globulin (SHBG)</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. In PCOS, there is typically a decrease in the levels of SHBG. Lower levels of SHBG result in increased bioavailability of testosterone, contributing to the hyperandrogenic symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In PCOS, biochemical changes include an elevated LH:FSH ratio, insulin resistance, increased levels of plasma testosterone, and decreased levels of SHBG. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 411 Speroff&rsquo;s Clinical Gynaecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48427,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12117,
    "choices": [
      {
        "id": 48432,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic ovaries</span></span></span></span></p>"
      },
      {
        "id": 48433,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis</span></span></span></span></p>"
      },
      {
        "id": 48434,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pelvic inflammatory disease</span></span></span></span></p>"
      },
      {
        "id": 48435,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing syndrome</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most likely diagnosis in a 28-year-old obese woman presenting with Oligomenorrhea, infertility and hirsutism?</span></span></span></span></p>",
    "unique_key": "Q6892119",
    "question_audio": null,
    "question_video": null,
    "map_id": 18822,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Polycystic ovaries</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A young woman presenting in the third decade with obesity, oligomenorrhea, infertility and hirsutism leaves no doubt for the diagnosis of PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">According to Rotterdam criteria &rarr; PCOD is diagnosed if any 2 of 3 of the following criteria are being fulfilled:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovulatory dysfunction such as oligomenorrhea or hyperandrogenism.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical or biochemical evidence of hyperandrogenism</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">USG criteria (1 or both ovaries showing polycystic appearance)</span></span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Since this woman has oligomenorrhea and hirsutism, SO2 of the criteria are being fulfilled.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is a condition where endometrial tissue grows outside the uterus. It commonly presents with painful periods, chronic pelvic pain, and can be associated with infertility. However, it does not typically present with hirsutism or oligomenorrhea as primary symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pelvic Inflammatory Disease (PID)</strong>: PID is an infection of the female reproductive organs, often caused by sexually transmitted infections. It typically presents with pelvic pain, fever, and abnormal vaginal discharge.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing Syndrome</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Cushing syndrome is caused by prolonged exposure to high levels of cortisol. It can present with obesity, menstrual irregularities, and hirsutism. However, the other symptoms of Cushing&#39;s syndrome (like a round face, high blood pressure, and purple stretch marks) are not mentioned, making PCOS a more likely diagnosis in this case.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Polycystic Ovary Syndrome (PCOS) should be highly suspected in women presenting with a combination of oligomenorrhea, infertility, hirsutism, and often obesity. PCOS is a complex endocrine disorder that impacts multiple aspects of health and is a common cause of infertility in women.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 400, Speroff&rsquo;s clinical Gynaecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48432,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12118,
    "choices": [
      {
        "id": 48436,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">17-OH progesterone</span></p>"
      },
      {
        "id": 48437,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">DHEA</span></p>"
      },
      {
        "id": 48438,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Testosterone</span></p>"
      },
      {
        "id": 48439,
        "text": "<p><span style=\"font-size:12.0pt;\">LH: FSH ratio</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Preeti, a 20-year-old girl presents with a history of rapidly developing hirsutism, severe acne and amenorrhea. Her BMI is 19. To establish the diagnosis, which would be the most appropriate blood test?</span></p>",
    "unique_key": "Q3941819",
    "question_audio": null,
    "question_video": null,
    "map_id": 18823,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ans. C. Testosterone</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:16px;\">For cases of virilisation and hirsutism, serum testosterone is the investigation of choice</span></p><p>&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">A variety of ovarian neoplasms, both benign and malignant may produce testosterone and lead to virilization. Specifically, women with an abrupt onset, typically within several months, or sudden worsening of virilizing signs should prompt concern for a hormone producing ovarian or adrenal tumour.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Symptoms may include deepening of voice, frontal balding, severe acne, or hirsutism or both, increased muscle mass and clitoromegaly.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Accordingly, serum testosterone levels may be used to exclude these tumours. Free testosterone levels are more sensitive than total testosterone levels as an indicator of hyperandrogenism.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">\"Threshold values beyond 200 ng/dl of total testosterone warrant evaluation for an ovarian lesion\".</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Testosterone estimation is the best investigation in case of rapid onset hirsutism and amenorrhea.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">M/C cause of rapid onset hirsutism in young females = Testosterone producing tumour</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">DHEA sulphate is produced exclusively by the adrenal gland. Therefore, serum DHEAS levels above 700 mcg/dl are highly sensitive&nbsp;for the presence of an adrenal neoplasm.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">Adrenal imaging with abdominal CT or MRI is indicated for any patient with DHEAS levels that exceed this value.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Let us look at each option separately:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option. A.</strong> <strong>17-OH Progesterone</strong>: This test is used to evaluate adrenal gland function and diagnose congenital adrenal hyperplasia (CAH), a condition that can cause symptoms similar to PCOS, including hirsutism and menstrual irregularities. However, the rapid onset of symptoms described is less typical for CAH.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option. B.</strong> <strong>DHEA (Dehydroepiandrosterone)</strong>: DHEA is an androgen produced by the adrenal glands. While elevated levels can contribute to hirsutism and acne, DHEA alone may not provide a definitive diagnosis in this case.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option C.</strong>&nbsp;<strong>Testosterone</strong>: Correct. Elevated levels of testosterone are a key indicator of hyperandrogenism, which can manifest as hirsutism, acne, and menstrual irregularities. Measuring testosterone levels is crucial in diagnosing conditions like PCOS or androgen-secreting tumors, which can present with rapid onset of symptoms.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option. D.</strong> <strong>LH: FSH Ratio</strong>: This ratio is often evaluated in the diagnosis of PCOS, as women with PCOS may have an elevated ratio. However, <strong>a normal ratio does not rule out PCOS, and it is not as directly indicative of hyperandrogenism as elevated testosterone levels.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">When evaluating a young woman with rapid onset of hirsutism, severe acne, and amenorrhea, measuring serum testosterone levels is crucial for diagnosing conditions associated with hyperandrogenism, such as PCOS or androgen-secreting tumors.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ref: Page 449, Speroff\u2019s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48438,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12120,
    "choices": [
      {
        "id": 48444,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligomenorrhea</span></span></span></span></p>"
      },
      {
        "id": 48445,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sonographic polycystic appearance of ovaries</span></span></span></span></p>"
      },
      {
        "id": 48446,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripheral distribution of follicles on transvaginal ultrasonography</span></span></span></span></p>"
      },
      {
        "id": 48447,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical signs of hyperandrogenism</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not included in Rotterdam criteria?</span></span></p>",
    "unique_key": "Q6164420",
    "question_audio": null,
    "question_video": null,
    "map_id": 18824,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Peripheral distribution of follicles on transvaginal ultrasonography</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligomenorrhea/ anovulation</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical or biochemical sign of hyperandrogenism</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasound features of polycystic ovaries</span></span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasound&nbsp;features which are considered for diagnosis of polycystic ovaries includes the presence of these in one or both ovaries</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ge;12 follicles measuring 2&ndash;9 mm throughout the entire ovary.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased ovarian volume of &gt; 10 cm3</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A single ovary complying these features is sufficient for diagnosing as polycystic <strong>ovaries(PCO) </strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us evaluate each option to identify which is not included in these criteria:</span></span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligomenorrhea</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Included. Oligomenorrhea, or infrequent menstrual periods, is one of the criteria under the Rotterdam guidelines for diagnosing PCOS. It reflects the chronic anovulation commonly seen in PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sonographic Polycystic Appearance of Ovaries</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Included. The presence of polycystic ovaries on ultrasound is a part of the Rotterdam criteria. This is typically defined as having 12 or more follicles in each ovary measuring 2-9 mm in diameter, or increased ovarian volume.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Peripheral Distribution of Follicles on Transvaginal Ultrasonography</strong>: Not included. While the presence of multiple follicles is a criterion, the specific pattern of their distribution, such as a peripheral arrangement, is not a requirement for the diagnosis of PCOS as per the Rotterdam criteria.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical Signs of Hyperandrogenism</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Included. Clinical signs of hyperandrogenism, such as hirsutism, acne, or androgenic alopecia, are part of the Rotterdam criteria. Alternatively, biochemical signs of hyperandrogenism can also fulfill this criterion.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The Rotterdam criteria for the diagnosis of PCOS include at least two of the following: oligomenorrhea or amenorrhea, clinical or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound. The specific distribution pattern of ovarian follicles is not a part of these diagnostic criteria.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 400, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48446,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12121,
    "choices": [
      {
        "id": 48448,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases LH production</span></span></span></span></p>"
      },
      {
        "id": 48449,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduces production of FSH</span></span></span></span></p>"
      },
      {
        "id": 48450,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acts on androgen receptors and antagonizes it</span></span></span></span></p>"
      },
      {
        "id": 48451,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduces ovarian androgen production</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 19y girl with PCOS is started on the combination pill shown below. What is the role of the progesterone component of this combination?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture10.jpg\" style=\"height:177px; width:300px\" /></span></span></span></span></p>",
    "unique_key": "Q9835423",
    "question_audio": null,
    "question_video": null,
    "map_id": 18825,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Reduces ovarian androgen production</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen production in PCOD women usually is an LH-dependent process. PROGESTINS in oral contraceptives suppress pituitary LH secretion and thus also suppress ovarian androgen production.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progestin in oral contraceptives inhibit 5&alpha; reductase activity in skin which decreases the production of dihydrotestosterone (DHT), the major nuclear androgen in hair follicles and sebaceous glands.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s consider the role of the progesterone component:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases LH Production</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. Progestins in oral contraceptive pills (OCPs), including Drosperinone, do not increase LH production. Instead, they help suppress ovulation partly by inhibiting the release of gonadotropins like LH from the pituitary gland.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduces Production of FSH</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Progestins contribute to the suppression of FSH production, which is a mechanism involved in preventing ovulation. However, this is not the most direct effect of drospirenone in the context of PCOS treatment.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Acts on Androgen Receptors and Antagonizes it</strong>: Drosperinone has anti-androgenic properties, meaning it can counteract the effects of androgens. This action helps reduce symptoms like acne and hirsutism in PCOS but is not its primary mechanism of action in terms of ovarian androgen production.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduces Ovarian Androgen Production</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. One of the key roles of drospirenone in OCPs for PCOS is to reduce ovarian androgen production. By suppressing gonadotropin release (LH and FSH), drospirenone reduces the stimulation of the ovaries, leading to decreased production of androgens.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In the treatment of PCOS, Drosperinone in combination oral contraceptive pills helps reduce ovarian androgen production by suppressing gonadotropin release. This action not only aids in regulating the menstrual cycle but also helps in managing hyperandrogenic symptoms such as acne and hirsutism commonly seen in PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 420, Speroff&rsquo;s Clinical Gynaecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48451,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 12122,
    "choices": [
      {
        "id": 48452,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgenic alopecia</span></span></span></span></p>"
      },
      {
        "id": 48453,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased facial hair</span></span></span></span></p>"
      },
      {
        "id": 48454,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clitoromegaly</span></span></span></span></p>"
      },
      {
        "id": 48455,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acne</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following features are seen in PCOS except?</span></span></span></span></p>",
    "unique_key": "Q5053520",
    "question_audio": null,
    "question_video": null,
    "map_id": 18826,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Clitoromegaly</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical features seen in PCOD are:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirsutism</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acne</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgenic alopecia</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased facial hair</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Menstrual irregularity</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In PCOD there is increased androgen production which is LH mediated and lead to growth of terminal hairs on the face or body in a male pattern</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clitoromegaly is not seen in PCOD.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirsutism defined as excessive male pattern facial and body hair</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Virilization is defined by the signs and symptoms of more severe androgen excess which include deepening of voice, clitoromegaly, balding and breast atrophy.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hair is characterized as <strong>vellus</strong> that is fine, soft, and unpigmented or <strong>terminal </strong>i.e long, coarse and pigmented</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In androgen sensitive areas androgen stimulates growth of longer, thicker, and darker hairs.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In hair follicles testosterone needs to be converted to dihydrotestosterone by 5&alpha; reductase. Dihydrotestosterone is the main hormone which plays a crucial role in hair growth.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Let us look at each option</strong>:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgenic Alopecia: Seen&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in PCOS. Androgenic alopecia, or male-pattern hair loss, can occur in PCOS due to the effects of elevated androgens on hair follicles.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased Facial Hair</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Seen in PCOS. Hirsutism, or increased facial and body hair in a male pattern, is a common feature of PCOS, resulting from increased androgen levels.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clitoromegaly</strong>: Not seen in PCOS. Clitoromegaly, or an enlarged clitoris, is a sign of virilization and is more indicative of conditions with severe androgen excess, such as congenital adrenal hyperplasia or androgen-secreting tumors. It is not a characteristic feature of PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acne</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Seen in PCOS. Acne is a common dermatological manifestation in PCOS, also related to elevated androgen levels.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Polycystic ovary syndrome (PCOS) is characterized by signs of hyperandrogenism, such as hirsutism, acne, and androgenic alopecia, along with menstrual irregularities. Clitoromegaly is not a typical feature of PCOS and is more indicative of conditions with more severe androgen excess. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 449, Speroff&rsquo;s Clinical Gynaecological Endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48454,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 12124,
    "choices": [
      {
        "id": 48460,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Insulin resistance</span></p>"
      },
      {
        "id": 48461,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Cushing syndrome</span></p>"
      },
      {
        "id": 48462,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Androgen producing tumors</span></p>"
      },
      {
        "id": 48463,
        "text": "<p><span style=\"font-size:12.0pt;\">Congenital adrenal hyperplasia</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"background-color:transparent;font-size:16px;\">During evaluation of PCOS, a serum 17 \u2013hydroxyprogesterone levels of 800 ng/dl was obtained. This value warrants the diagnosis of?</span></p>",
    "unique_key": "Q3245742",
    "question_audio": null,
    "question_video": null,
    "map_id": 18827,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D. Congenital adrenal hyperplasia</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">CONGENITAL ADRENAL HYPERPLASIA is caused by adrenal enzyme deficiency of most commonly 21 hydroxylase that results in excessive adrenal androgen production.</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Non classical or late onset CAH present later during life with signs of hyperandrogenism, very much like in PCOD.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Specific testing for CAH is usually reserved for those having early onset hirsutism (pre or peri-menarchal), women with family history of disorder and high-risk ethnic groups like Ashkenazi Jews.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A follicular phase morning serum 17 OHP concentration less than 200ng/dl, excludes and a level greater than 800 ng/dl establishes the diagnosis of CAH.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Between values of 200-800 ACTH stimulation test needs to be done with intramuscular injection of 0.25 mg ACTH , if the 17 OHP concentration will rise above 1500 mg/dL, it is diagnostic for CAH.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let us look at each option</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Insulin Resistance</strong>: Insulin resistance is a common feature of PCOS but is not directly indicated by elevated 17-hydroxyprogesterone levels. Insulin resistance is typically assessed through glucose tolerance tests or measurements of fasting insulin levels.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option. B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Cushing Syndrome</strong>: Cushing syndrome is characterized by excessive cortisol production. While it can present with features like PCOS, such as weight gain and menstrual irregularities, elevated 17-hydroxyprogesterone is not a typical finding in Cushing's.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Androgen Producing Tumors</strong>: Androgen-producing tumors can cause symptoms similar to PCOS. However, elevated 17-hydroxyprogesterone levels are more indicative of adrenal disorders like congenital adrenal hyperplasia rather than androgen-producing tumors.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. D.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Congenital Adrenal Hyperplasia (CAH)</strong>: Correct. Elevated levels of 17-hydroxyprogesterone are a key indicator for congenital adrenal hyperplasia, particularly the 21-hydroxylase deficiency form. In the context of PCOS evaluation, an abnormally high level of 17-hydroxyprogesterone warrants further investigation to exclude CAH.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">When evaluating a patient for PCOS, a significantly elevated level of 17-hydroxyprogesterone, as in this case, suggests the need to exclude congenital adrenal hyperplasia, especially the 21-hydroxylase deficiency variant. CAH can mimic many symptoms of PCOS, including hyperandrogenism and menstrual irregularities.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Page 449, Speroff\u2019s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48463,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12125,
    "choices": [
      {
        "id": 48464,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Male pattern hair growth on lower abdomen</span></p>"
      },
      {
        "id": 48465,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Thickened dark skin on inner thighs</span></p>"
      },
      {
        "id": 48466,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Abnormal glucose tolerance test results</span></p>"
      },
      {
        "id": 48467,
        "text": "<p><span style=\"color:black;font-size:12pt;\">High serum levels of high-density lipoproteins</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 19-year-old girl with a long-standing history of irregular menstrual cycles and amenorrhea presents with an ultrasound picture shown below. Which of the following is least likely to be seen in her?</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture11_c5RSZPQ.jpg\" alt=\"\" width=\"300\" height=\"229\"></span></p>",
    "unique_key": "Q4546560",
    "question_audio": null,
    "question_video": null,
    "map_id": 18828,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D.&nbsp;High serum levels of high-density lipoproteins</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">PCOD&nbsp;women shows chronic anovulation and commonly shows insulin resistance which is associated with acanthosis and thickening of skin.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Insulin resistance leads to abnormal glucose tolerance detected using GTT with 75 gm glucose.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Upto10% of women with PCOS develop diabetes by age 40.</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Metabolic abnormalities in PCOD</span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Elevated androgen level leads to increased LDL levels</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Increased triglyceride levels (&gt;150mg/dl)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Normal or decreased HDL levels(&lt;50mg/dl)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Hyperinsulinemia</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Central obesity with increased waist circumference (&gt;88 cm)</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let consider each option:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. A.</strong></span><span style=\"font-size:11pt;\"><strong> </strong></span><span style=\"font-size:12.0pt;\"><strong>Male Pattern Hair Growth on Lower Abdomen</strong>: Likely. Hirsutism, or male pattern hair growth, is a common feature in PCOS due to hyperandrogenism. This can include hair growth on the lower abdomen.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. B.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Thickened Dark Skin on Inner Thighs</strong>: Likely. Acanthosis nigricans, characterized by thickened and darkened skin, often in areas like the neck and inner thighs, is commonly associated with insulin resistance, a condition often seen in PCOS.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Abnormal Glucose Tolerance Test Results</strong>: Likely. Women with PCOS are at increased risk for insulin resistance and type 2 diabetes. An abnormal glucose tolerance test is a common finding and reflects impaired insulin sensitivity.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. D.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>High Serum Levels of High-Density Lipoproteins (HDL)</strong>: Least likely. PCOS is often associated with a dyslipidemic profile, which typically includes lower levels of HDL (\"good\" cholesterol) and higher levels of LDL (\"bad\" cholesterol) and triglycerides. <strong>High levels of HDL are not characteristic of the metabolic disturbances commonly seen in PCOS.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">PCOS is often associated with signs of hyperandrogenism like hirsutism, metabolic issues such as insulin resistance and abnormal glucose tolerance, and a dyslipidemic profile with lower HDL levels.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>&nbsp;Ref: Page 400, Speroff\u2019s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48467,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12128,
    "choices": [
      {
        "id": 48476,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Pancreas</span></span></span></span></p>"
      },
      {
        "id": 48477,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Adrenal</span></span></span></span></p>"
      },
      {
        "id": 48478,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ovary</span></span></span></span></p>"
      },
      {
        "id": 48479,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Pituitary</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During detailed workup of PCOD in a 19-year-old patient shown below is noted to have a serum total testosterone level of 375 ng/dl with rapidly increasing hirsutism. Which of the following endocrine glands is likely to harbour the androgen producing tumour?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture12_CA3vfPf.jpg\" style=\"height:195px; width:250px\" /></span></span></span></p>",
    "unique_key": "Q6129644",
    "question_audio": null,
    "question_video": null,
    "map_id": 18829,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C.&nbsp; Ovary </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shown is hirsutism. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When the serum total testosterone concentration (&gt;150ng/dl) or the clinical presentation suggests the possibility of rare androgen producing ovarian or adrenal tumours, remember that ovarian tumours are more common than adrenal tumours</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen secreting tumours of the ovary include</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sertoli-Leydig tumours</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">lipid cell tumours</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Theca cell tumours</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Brenners tumour</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Transvaginal ultrasound is gold standard to detect such tumour.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal tumours are identified by adrenal CT.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most androgen producing adrenal tumours are malignant.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenal adenomas are smaller than carcinoma and have smooth borders. CT features of irregular margin, necrosis, haemorrhage, or calcification suggest a carcinoma.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective ovarian venous catheterization can be considered for the rare patient having no demonstrable ovarian or adrenal mass lesion.</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s consider the potential source of an androgen-producing tumour:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pancreas</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The pancreas is not typically a source of androgen-producing tumours. It primarily functions in insulin and digestive enzyme production, and its pathologies are not usually associated with elevated androgen levels.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Adrenal tumours can produce androgens, leading to symptoms like hirsutism. However, ovarian tumours are more common causes of elevated androgens in women. Adrenal tumours are less frequent and are usually identified with adrenal CT imaging.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ovary</strong>: Correct. Ovarian tumours, such as Sertoli-Leydig cell tumours, lipid cell tumours, theca cell tumours, or Brenner tumours, can secrete high levels of androgens. Given the high serum testosterone level and the clinical presentation, an ovarian source is more likely than an adrenal source. Transvaginal ultrasound is typically used for initial evaluation.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O</span></span></strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ption. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pituitary</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Pituitary tumours, such as prolactinomas or adenomas producing ACTH, can affect menstrual cycles and hormonal balance, but they are not known for directly secreting androgens.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In cases of PCOD with significantly elevated serum testosterone levels and rapidly increasing hirsutism, an androgen-secreting ovarian tumour should be considered. Ovarian tumours are a more common source of excess androgens in women compared to adrenal tumours. Transvaginal ultrasound is the gold standard for detecting such ovarian tumours, while adrenal tumours are identified with adrenal CT imaging</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 449, Speroff&rsquo;s Clinical Gynaecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48478,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 12130,
    "choices": [
      {
        "id": 48484,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Insulin</span></span></span></span></p>"
      },
      {
        "id": 48485,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Dehydroepiandrosterone (DHEA)</span></span></span></span></p>"
      },
      {
        "id": 48486,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Metformin</span></span></span></span></p>"
      },
      {
        "id": 48487,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Progesterone</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications added to clomiphene has been found to be associated with improvement in ovulation response?</span></span></p>",
    "unique_key": "Q6041685",
    "question_audio": null,
    "question_video": null,
    "map_id": 18830,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Metformin</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Majority of both lean and obese women with PCOS ARE INSULIN RESISTANT</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin improves menstrual cyclicity and ovulatory function in women with PCOS.</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most appropriate candidate for treatment with metformin along with clomiphene are those:</span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">With impaired glucose tolerance or diabetes</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Those with obvious signs of insulin resistance such as acanthosis nigricans</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Women with features of metabolic syndrome such as obesity, dyslipidemia, and hypertension</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While insulin resistance is a common feature in PCOS, adding insulin itself is not a standard treatment for improving ovulation. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>&nbsp;</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DHEA is a precursor to sex hormones and is sometimes used as a supplement in various fertility treatments. However, its addition to clomiphene for improving ovulation response in PCOS is not well-established or widely recommended.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progesterone</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Progesterone is used in various contexts in reproductive medicine, but it is not typically added to clomiphene to improve ovulation. Its primary use is in the luteal phase support in assisted reproductive technologies and to induce menstrual cycles in cases of amenorrhea.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Metformin, when used alongside clomiphene, can improve the ovulation response in women with PCOS, particularly those with insulin resistance or metabolic syndrome. Metformin improves insulin sensitivity, thereby enhancing the effectiveness of clomiphene in inducing ovulation</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 424, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48486,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 12132,
    "choices": [
      {
        "id": 48492,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">20</span></span></span></span></p>"
      },
      {
        "id": 48493,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">30</span></span></span></span></p>"
      },
      {
        "id": 48494,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">40</span></span></span></span></p>"
      },
      {
        "id": 48495,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">50</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year nulligravida married for 4 years with irregular menstrual cycles was being evaluated for infertility. On ultrasonography she has 14 follicles measuring 2-8 mm diameter per ovary (USG picture shown below). What percentage of young women without PCOS will exhibit a similar ultrasonographic picture?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture13_I3ijK3t.jpg\" style=\"height:173px; width:250px\" /></span></span></p>",
    "unique_key": "Q3972192",
    "question_audio": null,
    "question_video": null,
    "map_id": 18831,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. 20</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8-25% of normal women and 14% of women using OCP meet the USG criteria for PCOD</span></span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thus option A) 20 % is correct.</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasound features which are considered for diagnosis of polycystic ovaries includes:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ge;12 follicles measuring 2&ndash;9 mm <em>throughout the entire ovary </em></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">increased ovarian volume of &gt; 10 cm3</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No subjective assessment of stromal echogenicity and/or follicular distribution pattern required. </span></span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A single ovary complying these features is sufficient for diagnosing as polycystic <strong>ovaries(PCO) </strong></span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Studies have demonstrated that without the symptoms of polycystic ovary syndrome, a PCO appearance alone is not associated with impaired fertility</span></span></strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While up to 25% of normal women can exhibit polycystic ovaries on ultrasound, it&#39;s crucial to remember that this finding alone, in the absence of clinical symptoms of PCOS, does not indicate impaired fertility or PCOS. The diagnosis of PCOS should be based on a combination of clinical signs, symptoms, and ultrasound findings</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 401, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48492,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 12134,
    "choices": [
      {
        "id": 48500,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"color:black\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reverses endometrial hyperplasia</span></span></span></span></p>"
      },
      {
        "id": 48501,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"color:black\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases angiotensinogen production</span></span></span></span></p>"
      },
      {
        "id": 48502,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"color:black\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduces LH levels in the blood</span></span></span></span></p>"
      },
      {
        "id": 48503,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"color:black\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases SHBG production</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old nulliparous female was advised the following contraceptives for irregular periods and hormonal imbalance. Ethinyl estradiol has which of the following effects?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture14_jD940aa.jpg\" style=\"height:148px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q3897882",
    "question_audio": null,
    "question_video": null,
    "map_id": 18832,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Increases SHBG production</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Estrogen &ndash; progestin contraceptives have several complimentary non contraceptive effect actions that make them effective treatment for menstrual irregularities and hirsutism seen in PCOD.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The high levels of estrogen in combination contraceptives stimulates hepatic production of SHBG thereby increasing binding capacity for circulating androgens and decreasing the amount of free active androgen.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Estrogen induces a dose dependent increase in SHBG concentrations.<br />\r\n\tEstrogen component also suppresses FSH in HPO axis</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us &nbsp;consider each option:</span></span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reverses Endometrial Hyperplasia</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While estrogens can influence the endometrium, they are not typically used alone to reverse endometrial hyperplasia. Progestins are more commonly used for this purpose, as unopposed estrogen can actually increase the risk of endometrial hyperplasia.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases Angiotensinogen Production</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Estrogens can increase the production of angiotensinogen in the liver, which can have effects on blood pressure regulation. However, this is not the primary reason for using ethinyl estradiol in combination contraceptives for menstrual irregularities and hormonal imbalance.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Reduces LH Levels in the Blood</strong>: Estrogen components in oral contraceptives can suppress LH secretion as part of the feedback mechanism on the hypothalamic-pituitary-ovarian axis. However, this suppression is typically achieved in combination with a progestin component.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increases SHBG Production</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. Ethinyl estradiol stimulates hepatic production of sex hormone-binding globulin (SHBG), which binds free testosterone in the bloodstream, thus reducing the level of free and bioavailable androgens. This effect is beneficial in conditions like PCOS, where hyperandrogenism is a concern.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The estrogen component of combination contraceptives, such as ethinyl estradiol, increases the production of sex hormone-binding globulin (SHBG) in the liver. This leads to a reduction in free and bioavailable androgens, which can be beneficial in managing conditions like PCOS that are characterized by hyperandrogenism. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 425, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48503,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12136,
    "choices": [
      {
        "id": 48508,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">It should be performed as 1<sup>st</sup> line of treatment in women seeking fertility issues in PCOS</span></span></span></span></p>"
      },
      {
        "id": 48509,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A minimum of 10 drills in each ovary should be made</span></span></span></span></p>"
      },
      {
        "id": 48510,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">It is used to mainly treat </span></span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">hirsutism</span></span></span></p>"
      },
      {
        "id": 48511,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">It can lead to a reduction in AMH levels</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30yr subfertile&nbsp; woman who has not responded to ovulation induction with clomiphene citrate undergoes a procedure as shown.&nbsp; What is true about the procedure being shown?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/27/picture15_vtXSqXI.jpg\" style=\"height:187px; width:250px\" /></span></span></span></p>",
    "unique_key": "Q5009895",
    "question_audio": null,
    "question_video": null,
    "map_id": 18833,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. It can lead to a reduction in AMH levels</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The procedure shown in Laparoscopic Ovarian Drilling</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Laparoscopic ovarian drilling is used in place of wedge resection (earlier done) in patients with severe PCOS resistant to clomiphene and have even tried ovulation with gonadotropins </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procedure involves use of electrocautery monopolar needle inserted at a cutting current of 100 W for entry and <strong>40W</strong> coagulation to treat stroma for a time of <strong>4 seconds. </strong>In each ovary <strong>4 punctures </strong>are done to reduce adhesion formation to a depth of <strong>4 mm (rule of 4)</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most of the studies report reduction in both androgen and LH concentration and an increase in FSH concentration.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is a fall in AMH levels following the procedure </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, there is risk of adhesion formation in patients and should be discussed with the patient.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The beneficial effects are sustained for up to 5 years.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s evaluate each statement about this procedure:</span></span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be Performed as 1st Line of Treatment in Women Seeking Fertility Issues in PCOS</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. Ovarian drilling is not the first line of treatment for fertility issues in women with PCOS. Initial treatments usually involve lifestyle modifications and medications like clomiphene citrate or letrozole for ovulation induction. Ovarian drilling is considered when these initial treatments fail.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Minimum of 10 Drills in Each Ovary Should be Made</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. The exact number of drills made during ovarian drilling is variable and depends on the surgeon&#39;s discretion and the patient&#39;s specific condition. However, making too many drills can damage the ovarian tissue and is not typically recommended.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Used to Mainly Treat Hirsutism</strong>: Incorrect. Ovarian drilling is primarily used to induce ovulation in women with PCOS who are resistant to other forms of treatment. While it may have some effect on androgen levels, its main purpose is not to treat hirsutism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can Lead to a Reduction in AMH Levels</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. Ovarian drilling can lead to a reduction in anti-M&uuml;llerian hormone (AMH) levels. AMH is a marker of ovarian reserve, and ovarian drilling, by its nature, can reduce the number of antral follicles, thereby decreasing AMH levels.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Ovarian drilling is a surgical option for inducing ovulation in women with PCOS who are resistant to first-line treatments like clomiphene citrate. While it can be effective in inducing ovulation, it can also lead to a reduction in AMH levels, indicating a decrease in ovarian reserve. It is not primarily used for treating hirsutism and should not be the first-line treatment for fertility issues in PCOS</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 424, Speroff&rsquo;s Clinical Gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48511,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 12138,
    "choices": [
      {
        "id": 48516,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Metformin</span></p>"
      },
      {
        "id": 48517,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">HMG</span></p>"
      },
      {
        "id": 48518,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Clomiphene</span></p>"
      },
      {
        "id": 48519,
        "text": "<p><span style=\"font-size:12.0pt;\">Ormeloxifene</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">All the following are ovulation induction option in PCOD except?</span></p>",
    "unique_key": "Q2801003",
    "question_audio": null,
    "question_video": null,
    "map_id": 18834,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D. Ormeloxifene</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Polycystic ovarian syndrome is a common disorder relating to ovulation problems</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The 1<sup>st</sup> line of management in a woman desirous of fertility in PCOS in Letrozole (Recent ESHRE guidelines)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Earlier Clomiphene citrate was the drug of choice but has mostly been replaced with letrozole.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Gonadotropins are used when there is inability to induce ovulation with letrozole or clomiphene. Gonadotropins are used in clomiphene failure.&nbsp; (2<sup>nd</sup> line management)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">When PCOD women do not ovulate with gonadotropins laparoscopic ovarian drilling is planned.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Metformin in combination with clomiphene increases ovulation and pregnancy rate as compared to clomiphene alone.</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Ormeloxifene (Centchroman) is</span></p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A Selective Estrogen Receptor Modulator</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It is a&nbsp; non-steroidal oral contraceptive used in a dose of 30mg twice weekly for 3 months and then weekly dose for contraception</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It is also used for heavy menstrual bleeding in 60 mg twice weekly.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It does not induce ovulation.</span></p></li></ul></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let us look at the other options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. A.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Metformin</strong>: Metformin is used in PCOS primarily for its insulin-sensitizing effects, which <strong>can help restore normal ovulation</strong>, especially in women with insulin resistance. It's often used in combination with other ovulation-inducing drugs.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. B.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Human Menopausal Gonadotropin (HMG)</strong>: HMG, which contains a mixture of FSH and LH, is used to induce ovulation in women who do not respond to clomiphene. It directly stimulates the ovaries to produce follicles.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C. Clomiphene</strong>: Clomiphene citrate is a first-line therapy for ovulation induction in women with PCOS. It works by blocking estrogen receptors, leading to increased release of FSH and LH, which in turn stimulates follicular growth.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In PCOS, ovulation induction can be achieved with medications like clomiphene citrate, metformin (particularly in insulin-resistant patients), and human menopausal gonadotropin (HMG). Ormeloxifene, however, is not used for this purpose and is instead utilized for contraception and managing dysfunctional uterine bleeding.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Page 424, Speroff\u2019s Clinical Gynecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48519,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 12140,
    "choices": [
      {
        "id": 48524,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More chances of multiple pregnancy</span></span></span></span></p>"
      },
      {
        "id": 48525,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More chances of ovulation</span></span></span></span></p>"
      },
      {
        "id": 48526,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No antiestrogenic effect on endometrium</span></span></span></span></p>"
      },
      {
        "id": 48527,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased chances of poly-follicular development</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 23y old woman with PCOS and infertility is started on letrozole for ovulation induction. Letrozole is nowadays preferred over clomiphene in case of PCOS due to which of the following effect?</span></span></p>",
    "unique_key": "Q1027189",
    "question_audio": null,
    "question_video": null,
    "map_id": 18835,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C.&nbsp; No antiestrogenic effect on endometrium</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Letrozole is an aromatase inhibitor. Orally absorbed and t&frac12; is 45h </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene vs Letrozole:</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/18/screenshot-2024-03-18-152100.jpg\" style=\"height:416px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">let&#39;s examine each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More Chances of Multiple Pregnancy</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. Letrozole actually has a lower risk of multiple pregnancies compared to clomiphene. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More Chances of Ovulation</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While letrozole has been shown to be effective in inducing ovulation, especially in women with PCOS, its preference over clomiphene is not solely based on a higher ovulation rate. Both medications are effective for ovulation induction.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>No Antiestrogenic Effect on Endometrium</strong>: Correct. One of the key advantages of letrozole over clomiphene is that it does not have the antiestrogenic effects on the endometrium and cervical mucus that clomiphene does. Clomiphene can lead to a thin endometrial lining, which can be counterproductive for conception.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased Chances of Poly-Follicular Development</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect. Letrozole typically results in a more physiologic ovulation process with fewer risks of poly-follicular development compared to clomiphene.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Letrozole is often preferred over clomiphene for ovulation induction in women with PCOS due to its lack of antiestrogenic effects on the endometrium. While both letrozole and clomiphene are effective in inducing ovulation, letrozole&#39;s more favorable impact on the endometrial lining makes it a better choice in certain scenarios, particularly in women with PCOS</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 424, Speroff&rsquo;s Clinical Gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48526,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 12141,
    "choices": [
      {
        "id": 48528,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin resistance</span></span></span></span></p>"
      },
      {
        "id": 48529,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acanthosis Nigricans</span></span></span></span></p>"
      },
      {
        "id": 48530,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dyslipidemia</span></span></span></span></p>"
      },
      {
        "id": 48531,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperandrogenism</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common metabolic abnormality associated with PCOS is?<strong> &nbsp;</strong></span></span></p>",
    "unique_key": "Q4033156",
    "question_audio": null,
    "question_video": null,
    "map_id": 18836,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Insulin Resistance</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin resistance is indeed one of the most common metabolic abnormalities associated with PCOS. It is a key factor in the pathophysiology of the syndrome and contributes to various other metabolic complications, including type 2 diabetes.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nearly 70% have at least one borderline or elevated lipid level. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prevalence of obesity is around 50% in PCOS </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metabolic abnormalities in PCOD</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated androgen level leads to increased LDL levels</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased triglyceride levels (&gt;150mg/dl)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal or decreased HDL levels(&lt;50mg/dl)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperinsulinemia</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Central obesity with increased waist circumference (&gt;88 cm)</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acanthosis Nigricans</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Acanthosis nigricans, a skin condition characterized by darkened and thickened patches, often in the neck and groin areas, is associated with insulin resistance, a common feature in PCOS. However, it is more of a clinical sign than a metabolic abnormality.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperandrogenism</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Hyperandrogenism, while a defining feature of PCOS, is more of an endocrine abnormality than a metabolic one. It manifests clinically as hirsutism, acne, and alopecia.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The most common metabolic abnormality associated with PCOS is insulin resistance, which plays a central role in the pathophysiology of the syndrome and is linked to various metabolic complications. While dyslipidaemia is also common in PCOS, insulin resistance is more fundamental to the disorder&#39;s metabolic disturbances.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ref: Page 449,416, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</strong></span></span></span></span></p>",
    "correct_choice_id": 48528,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 12143,
    "choices": [
      {
        "id": 48536,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian malignancy</span></span></span></span></p>"
      },
      {
        "id": 48537,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstructive sleep apnoea</span></span></span></span></p>"
      },
      {
        "id": 48538,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial hyperplasia</span></span></span></span></p>"
      },
      {
        "id": 48539,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast malignancy</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are long term effects of PCOS except?</span></span></p>",
    "unique_key": "Q4959948",
    "question_audio": null,
    "question_video": null,
    "map_id": 18837,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D.&nbsp; Breast malignancy</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management of PCOD should correct both its immediate and long-term clinical consequences which include:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Menstrual irregularities</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of developing <strong>endometrial hyperplasia and neoplasia</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperandrogenism</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of developing <strong>type 2 DM</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of developing <strong>cardiovascular disease</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OBESITY&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and associated <strong>obstructive sleep apnea</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase in prevalence of <strong>anxiety, depression, and mood disorders</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metabolic syndrome</span></span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Even though PCOD is associated with Hyperestrogenic state there is no positive correlation with breast carcinoma and PCOD.</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let&#39;s analyze each option to determine which is not a long-term effect:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian Malignancy</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While PCOS is associated with a number of reproductive and metabolic complications, a direct link between PCOS and increased risk of ovarian cancer is not clearly established. PCOS is primarily associated with an increased risk of endometrial hyperplasia and cancer due to prolonged unopposed estrogen exposure.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstructive Sleep Apnoea</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. Obstructive sleep apnea is more common in women with PCOS, often related to the higher prevalence of obesity in this population. Obesity, a common feature in PCOS, is a risk factor for obstructive sleep apnoea.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Endometrial Hyperplasia</strong>: Correct. Women with PCOS are at an increased risk of endometrial hyperplasia and endometrial cancer due to chronic anovulation, leading to prolonged estrogen exposure without the counterbalancing effect of progesterone.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast Malignancy</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: exception. Despite the hyperestrogenic state associated with PCOS, there is no established positive correlation between PCOS and an increased risk of breast cancer. The increased risk of malignancy in PCOS is more specifically related to the endometrium.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While PCOS is associated with several long-term health consequences, including menstrual irregularities, infertility, metabolic syndrome, type 2 diabetes, cardiovascular disease, and endometrial hyperplasia, there is no established direct link between PCOS and an increased risk of breast cancer. The management of PCOS should address both its immediate symptoms and long-term health risks.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 416, Speroff&rsquo;s Clinical Gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></p>",
    "correct_choice_id": 48539,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 12144,
    "choices": [
      {
        "id": 48540,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flow cytometry of the peripheral blood</span></span></span></span></p>"
      },
      {
        "id": 48541,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum cortisol levels</span></span></span></span></p>"
      },
      {
        "id": 48542,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum 17-hydroxyprogesterone levels</span></span></span></span></p>"
      },
      {
        "id": 48543,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum TSH</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An infant is born with ambiguous genitalia. Although amniocentesis analysis during pregnancy showed a 46XX genotype, this infant has phallic-appearing genitalia and partially fused labia. You cannot palpate testes. Aside from a standard blood test, which biochemical screen is indicated?</span></span></p>",
    "unique_key": "Q7465395",
    "question_audio": null,
    "question_video": null,
    "map_id": 18838,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C.&nbsp; Serum 17-hydroxyprogesterone levels</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This infant likely has congenital adrenal hyperplasia (CAH).</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The classic form of 21-hydroxylase deficiency (21-OHD) is the most common cause of CAH.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has an incidence between 1 in 10,000 and 1 in 15,000 and is the most common cause of androgenization in chromosomal 46,XX females. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Affected individuals are homozygous or compound heterozygous for severe mutations in the enzyme 21-hydroxylase (<em>CYP21A2</em>). This mutation causes a block in adrenal glucocorticoid and mineralocorticoid synthesis, increasing 17-hydroxyprogesterone and shunting steroid precursors into the androgen synthesis pathway.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased androgen synthesis in utero causes androgenization of the 46,XX fetus in the first trimester. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ambiguous genitalia are seen at birth, with varying degrees of clitoral enlargement and labial fusion. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The salt-wasting form of 21-OHD results from severe combined glucocorticoid and mineralocorticoid deficiency. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A salt-wasting crisis usually manifests between 5 and 21 days of life and is a potentially life-threatening event that requires urgent fluid resuscitation and steroid treatment. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thus, a diagnosis of 21-OHD should be considered in any baby with atypical genitalia with bilateral non palpable gonads.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flow Cytometry of the Peripheral Blood</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Flow cytometry is not typically used in the initial evaluation of ambiguous genitalia. It is more commonly used for immunological analyses and is not directly relevant to determining the cause of ambiguous genitalia.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum Cortisol Levels</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While serum cortisol levels might be relevant in cases of adrenal insufficiency, they are not the most direct initial test for an infant with ambiguous genitalia. Cortisol levels may be part of the broader evaluation but are not the primary test for diagnosing congenital adrenal hyperplasia (CAH).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum TSH</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is used to screen for thyroid disorders but is not the primary test for evaluating ambiguous genitalia. TSH levels would not typically be elevated in cases of CAH or other conditions leading to virilization.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In infants with ambiguous genitalia and a 46XX genotype, serum 17-hydroxyprogesterone levels should be assessed to screen for congenital adrenal hyperplasia, particularly 21-hydroxylase deficiency. This condition leads to increased androgen synthesis, causing virilization in chromosomal 46, XX females. Prompt diagnosis is crucial for appropriate management and prevention of potentially life-threatening adrenal crises.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Ref: Page 266, Speroff&rsquo;s Clinical Gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48542,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 12146,
    "choices": [
      {
        "id": 48548,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Turner&rsquo;s syndrome</span></span></span></span></p>"
      },
      {
        "id": 48549,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pituitary adenoma</span></span></span></span></p>"
      },
      {
        "id": 48550,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;PCOS</span></span></span></span></p>"
      },
      {
        "id": 48551,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral dysgerminoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A young lady presents to the Gynecology OPD with complaints of primary infertility, excessive weight gain and hirsutism. Laparoscopy shows the following finding. What is the most likely diagnosis? </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/02/picture1.jpg\" style=\"height:227px; width:266px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>",
    "unique_key": "Q5150173",
    "question_audio": null,
    "question_video": null,
    "map_id": 18839,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. PCOS&nbsp; </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Laparoscopic image shows bilaterally enlarged ovaries seen in Polycystic ovary syndrome</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PCOS is a common functional disorder of the ovaries of unknown etiology. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A diagnosis of PCOS must meet 2 out of 3 criteria: Rotterdam Criteria</span></span></span></span>\r\n\t<ol>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen excess with clinical hyperandrogenism or elevated serum free or total testosterone</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian dysfunction with oligo/anovulation </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasound showing polycystic morphology in 1 or both ovaries. </span></span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong><strong> </strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Turner&rsquo;s Syndrome:</strong> Turner&rsquo;s syndrome is characterized by the presence of a single X chromosome (45XO) and is typically associated with features such as short stature, webbed neck, and primary amenorrhea. It is not associated with PCOS-like symptoms or the laparoscopic findings described.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pituitary Adenoma</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A pituitary adenoma can cause menstrual irregularities and infertility due to hormonal imbalances, particularly if it is a prolactin-secreting adenoma. However, it would not cause the specific laparoscopic findings associated with PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral Dysgerminoma</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bilateral dysgerminoma is a rare type of ovarian tumor. The presentation would be more acute and could include abdominal pain or a palpable mass, which are not described in this scenario. The laparoscopic findings typical for PCOS are not consistent with dysgerminoma.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The most likely diagnosis for a young woman presenting with primary infertility, weight gain, hirsutism, and characteristic laparoscopic findings of enlarged, polycystic ovaries is PCOS. PCOS is a common endocrine disorder that affects women of reproductive age and is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 400, Speroff&rsquo;s Clinical Gynecological Endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48550,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 12149,
    "choices": [
      {
        "id": 48560,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ectopic pregnancy </span></span></span></span></p>"
      },
      {
        "id": 48561,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">PCOS</span></span></span></span></p>"
      },
      {
        "id": 48562,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Endometriosis </span></span></span></span></p>"
      },
      {
        "id": 48563,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">PID</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pearl necklace appearance is characteristic in?</span></span></span></span></p>",
    "unique_key": "Q2862718",
    "question_audio": null,
    "question_video": null,
    "map_id": 18840,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. PCOS</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">POLYCYSTIC OVARIAN DISEASE (PCOD)</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a heterogeneous syndrome complex.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Characterized by chronic anovulation and hyperandrogenism.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Frequently associated with insulin resistance, resulting in menstrual irregularity, infertility &amp; hirsutism</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnosis</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rotterdam 2003 criteria for diagnosis of PCOS/PCOD&mdash;at least two out of three should be present</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligo/anovulation</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperandrogenism: biochemical or clinical</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On USG: Twelve or more than 12 follicles 2&ndash;9 mm in size present within one or both ovaries on USG and/or ovarian volume &gt;10 mL.</span></span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Principles of management include:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Irregular periods/amenorrhea = regularization of menses with OC pills/cyclical progesterone</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirsutism/acne = suppression of androgens</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility = ovulation induction (preferred drug: Letrozole; Clomiphene citrate can also be given; 2<sup>nd</sup> line of drugs: Gonadotropins)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin sensitizers like metformin&nbsp; are also used to tackle insulin resistance</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ectopic Pregnancy</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The embryo implants outside the uterine cavity (most commonly in the fallopian tube). They might show an adnexal mass and an absence of an intrauterine gestational sac.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Endometriosis</strong>: It involves the growth of endometrial tissue outside the uterus, ultrasound findings vary and can include cysts (endometriomas) or adhesions.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PID (Pelvic Inflammatory Disease)</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In PID, an infection of the female reproductive organs, ultrasound findings might include thickened fluid-filled fallopian tubes or other signs of inflammation. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The &quot;pearl necklace&quot; appearance on ultrasound, characterized by multiple small follicles around the periphery of the ovary, is a hallmark sign of PCOS. This appearance helps in the diagnosis of PCOS, a common endocrine disorder in women of reproductive age.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 400, Speroff&rsquo;s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48561,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 12150,
    "choices": [
      {
        "id": 48564,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OC pills </span></span></span></span></p>"
      },
      {
        "id": 48565,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclical progesterone</span></span></span></span></p>"
      },
      {
        "id": 48566,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myoinositol </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>"
      },
      {
        "id": 48567,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Danazol</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is not used in PCOS? </span></span></p>",
    "unique_key": "Q9205764",
    "question_audio": null,
    "question_video": null,
    "map_id": 18841,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Danazol</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">POLYCYSTIC OVARIAN DISEASE (PCOD)</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a heterogeneous syndrome complex.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Characterized by chronic anovulation and hyperandrogenism.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Frequently associated with insulin resistance, resulting in menstrual irregularity, infertility &amp; hirsutism</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnosis</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rotterdam 2003 criteria for diagnosis of PCOS/PCOD&mdash;at least two out of three should be present</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oligo/anovulation</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperandrogenism: biochemical or clinical</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On USG: Twelve or more than 12 follicles 2&ndash;9 mm in size present within one or both ovaries on USG and/or ovarian volume &gt;10 mL.</span></span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Principles of management include:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Irregular periods/amenorrhea = regularization of menses with OC pills/cyclical progesterone</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirsutism/acne = suppression of androgens</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility = ovulation induction (preferred drug: Letrozole; Clomiphene citrate can also be given; 2<sup>nd</sup> line of drugs: Gonadotropins)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin sensitizers like metformin&nbsp; are also used to tackle insulin resistance</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OC Pills (Oral Contraceptive Pills)</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Commonly prescribed in PCOS for regularizing menstrual cycles, decreasing androgen levels, and improving symptoms such as hirsutism and acne.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclical Progesterone</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Cyclical progesterone can be used to induce regular menstrual bleeding, thereby reducing the risk of endometrial hyperplasia, which can result from anovulation and prolonged estrogen exposure in PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Myo-Inositol</strong>: Myo-inositol is a supplement that has been shown to improve insulin resistance and ovarian function in women with PCOS, and it may help in restoring fertility and normalizing menstrual cycles.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Danazol</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Not used in PCOS. Danazol is an androgenic medication primarily used in the treatment of endometriosis and fibrocystic breast disease. Due to its androgenic effects, it is not suitable for treating PCOS, a condition already characterized by hyperandrogenism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In PCOS, treatment options include oral contraceptive pills, cyclical progesterone, and supplements like myo-inositol, which help in managing symptoms and reducing long-term risks. Danazol, due to its androgenic properties, is not used in PCOS management, as it may exacerbate symptoms related to hyperandrogenism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 424, Speroff&rsquo;s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48567,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 12152,
    "choices": [
      {
        "id": 48572,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;Bishop score </span></span></span></span></p>"
      },
      {
        "id": 48573,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;Rotterdam criteria</span></span></span></span></p>"
      },
      {
        "id": 48574,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;Ferriman-Gallwey score </span></span></span></span></p>"
      },
      {
        "id": 48575,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;All of the above</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is used in quantifying hirsutism?</span></span></p>",
    "unique_key": "Q6848931",
    "question_audio": null,
    "question_video": null,
    "map_id": 18843,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Ferriman-Gallwey score</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Ferriman-Gallwey Score: Method used for evaluating and quantifying hirsutism in women.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a score which quantifies the amount of hair (1-4) in 9 areas of the body (upper lip/ chin/ upper back/ lower back/ breast/ upper abdomen/ lower abdomen/ upper arm/ thighs)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A score of &gt; 8 is significant to call it clinical hyperandrogenism</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at the other options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bishop Score</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The Bishop score is used in obstetrics to assess the readiness of the cervix for labor, evaluating factors such as dilation, effacement, station, consistency, and position of the cervix</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rotterdam Criteria</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The Rotterdam criteria are used for diagnosing polycystic ovary syndrome (PCOS). They include hyperandrogenism (clinical or biochemical), oligo/anovulation, and polycystic ovaries on ultrasound.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the Above</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Incorrect, as only the Ferriman-Gallwey score is used for quantifying hirsutism. The Bishop score and Rotterdam criteria serve different purposes in obstetrics and PCOS diagnosis, respectively.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The Ferriman-Gallwey score is the standardized method used to quantify the extent and severity of hirsutism. It assesses hair growth in various areas of the body that are typically less hairy in females, providing a useful tool in diagnosing and assessing the severity of conditions like PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 450, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48574,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 12153,
    "choices": [
      {
        "id": 48576,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Acne</span></p>"
      },
      {
        "id": 48577,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Alopecia</span></p>"
      },
      {
        "id": 48578,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Clitoromegaly</span></p>"
      },
      {
        "id": 48579,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Testosterone level of 150 ng/dl</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following findings favor the diagnosis of androgenic tumor over PCOS in a woman presenting with amenorrhea and hirsutism?</span></p>",
    "unique_key": "Q6725010",
    "question_audio": null,
    "question_video": null,
    "map_id": 18844,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. C. Clitoromegaly</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>CLINICAL FEATURES OF PCOS:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">MC - Anovulatory infertility/amenorrhea/oligomenorrhea</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Sometimes menorrhagia</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Acanthosis nigricans \u2013 cutaneous marker of IR</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Hirsutism</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Thick terminal hair with male pattern of distribution</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Acne</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Alopecia</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Ferriman gallwey scoring \u2265 8</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Virilization \u2013 NEVER SEEN (seen in androgenic tumors)</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Clitoromegaly</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Hoarseness of voice</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Increased muscle mass</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Male pattern baldness</strong></span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let us look at each option:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. A.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Acne</strong>: Acne is a common symptom of PCOS due to hyperandrogenism</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. B.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Alopecia</strong>: Androgenic alopecia (male-pattern hair loss) can occur in both PCOS and androgenic tumors due to increased androgen levels.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Clitoromegaly</strong>: Correct. Clitoromegaly, or enlargement of the clitoris, is a sign of significant androgen excess and is more suggestive of an androgen-secreting tumor than PCOS.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. D.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Testosterone Level of 150 ng/dl</strong>: While elevated testosterone levels are seen in PCOS, a level as high as 150 ng/dl is unusual and would raise suspicion for an androgen-secreting tumor. However, clitoromegaly is a more definitive clinical sign that favours an androgenic tumor over PCOS.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Clitoromegaly is a key clinical finding that favours the diagnosis of an androgen-secreting tumor over PCOS in a woman presenting with amenorrhea and hirsutism. This sign indicates a higher level of androgen excess than typically seen in PCOS. In contrast, symptoms like acne and alopecia can occur in both conditions.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Page 449, Speroff\u2019s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48578,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 12158,
    "choices": [
      {
        "id": 48596,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"color:black\">A, B &amp; C are correct </span></span></span></p>"
      },
      {
        "id": 48597,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"color:black\">A &amp; B are correct </span></span></span></p>"
      },
      {
        "id": 48598,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"color:black\">C, D &nbsp;&amp; E are correct</span></span></span></p>"
      },
      {
        "id": 48599,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"color:black\">D &amp; E are correct</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasonographic criteria for the diagnosis of PCOD include?</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Number of follicles/ovaries </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian volume </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal volume </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal echogenicity </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal blood flow</span></span></span></span></li>\r\n</ol>",
    "unique_key": "Q4168477",
    "question_audio": null,
    "question_video": null,
    "map_id": 18845,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. A &amp; B are correct</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">According to the consensus definition, polycystic ovaries are present when:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">One or both ovaries demonstrate 12 or more follicles measuring 2-9 mm in diameter <strong>and/or</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;The ovarian volume exceeds 10 cm<sup>3</sup>. </span></span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only one ovary meeting either of these criteria is sufficient to establish the presence of polycystic ovaries </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal Echogenicity and Volume have been described, but do not contribute to formal diagnostic criteria. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal blood flow is not included in ultrasonographic diagnostic criteria for PCOD</span></span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Updated Ultrasonographic criteria for the diagnosis of PCOD by ESHRE guidelines 2018</span></span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovaries may be normal in PCOS, and conversely, polycystic ovarian morphology (PCOM) may be seen in women without the syndrome. However, it is well accepted that women with PCOS tend to have larger ovaries with an increased number of follicles. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The updated diagnostic criteria at the time of review are based on a 2018 International consensus guideline (ESHRE guideline)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients &gt; 8 years post menarche, and using a high-frequency endo-vaginal probe &nbsp;(8MHz)</span></span></span></span>\r\n\t<ol style=\"list-style-type:lower-roman\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follicle number per ovary (FNPO) &ge; 20, and/or </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian volume &ge;10 mL, ensuring no corpora lutea, cysts or dominant follicles are present </span></span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If using transabdominal scanning, or older technology where ovarian morphology is not well visualized, consider using the ovarian volume threshold of &ge;10 ml on either ovary. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The diagnostic criteria are adjusted in adolescent females (defined as within 8 years of menarche, or age &lt;20 years), in whom ultrasound should not be used for the diagnosis of PCOS due to the high incidence of multi-follicular ovaries in this life stage. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This supersedes the initial Rotterdam criteria of &ge; 12 follicles. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of a single multi-follicular ovary is sufficient to provide the sonographic criterion for PCOS </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other morphological features have been described, but do not contribute to formal diagnostic criteria:</span></span></span></span>\r\n\t<ol style=\"list-style-type:lower-roman\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal Echogenicity and Volume (hyperechoic central stroma) </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripheral location of follicles (string of pearls sign) </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follicles of similar size measuring 2-9 mm </span></span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us look at each option:</span></span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Number of Follicles/Ovaries</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. One of the criteria for PCOS on ultrasound is the presence of a high number of follicles in the ovaries. According to the Rotterdam criteria, this is typically defined as 12 or more follicles measuring 2-9 mm in diameter in each ovary.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian Volume</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. Another ultrasonographic criterion for PCOS is increased ovarian volume. The Rotterdam criteria define this as an ovarian volume greater than 10 cm&sup3;.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Stromal Volume</strong>: While stromal volume may be increased in PCOS, it is not a specific criterion for the diagnosis on ultrasound. The diagnosis is more commonly based on the number of follicles and ovarian volume.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stromal Echogenicity</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Increased stromal echogenicity can be seen in PCOS, but it is not part of the standard criteria fordiagnosis on ultrasound.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option. E.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Stromal Blood Flow</strong>: Changes in stromal blood flow may occur in PCOS; however, it is not a defined criterion for its diagnosis in ultrasonography.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The correct answer is <strong>B)&nbsp;A &amp; B are correct</strong>, as the number of follicles per ovary and ovarian volume are key ultrasonographic criteria for diagnosing PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The ultrasonographic criteria for diagnosing PCOS include the presence of 12 or more follicles measuring 2-9 mm in diameter per ovary and/or increased ovarian volume (&gt;10 cm&sup3;). These criteria are part of the Rotterdam criteria for the diagnosis of PCOS and are essential in the assessment of this condition</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 401, Speroff&rsquo;s clinical gynecological endocrinology and infertility 9<sup>th</sup> edition</span></span></strong></p>",
    "correct_choice_id": 48597,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 12160,
    "choices": [
      {
        "id": 48604,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">TSH</span></span></span></span></p>"
      },
      {
        "id": 48605,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">LH</span></span></span></span></p>"
      },
      {
        "id": 48606,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Urinary ketosteroids</span></span></span></span></p>"
      },
      {
        "id": 48607,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">HCG</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In galactorrhea-amenorrhea syndrome, the investigation you should advise apart from serum prolactin levels is? </span></span></span></span></p>",
    "unique_key": "Q7254386",
    "question_audio": null,
    "question_video": null,
    "map_id": 18846,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. TSH</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperprolactinemia leads to both galactorrhea and amenorrhea. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prolactin secretion is controlled by a prolactin inhibitor factor that is secreted from the hypothalamus.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other factors like vasoactive inhibitory peptide (VIP) and thyroid releasing hormone (TRH) cause increased prolactin secretion. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In fact, TRH in addition to increasing TSH causes a rise in prolactin levels. In patients with galactorrhea-amenorrhea S.TSH should be evaluated. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperprolactinemia leads to both galactorrhea and amenorrhea. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 401, Speroff&rsquo;s Clinical Gynecological Endocrinology, and Infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48604,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 12161,
    "choices": [
      {
        "id": 48608,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Elevated LH, ratio of LH/FSH is &gt; 3:1</span></span></span></span></p>"
      },
      {
        "id": 48609,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reversible estradiol: estrone ratio</span></span></span></span></p>"
      },
      {
        "id": 48610,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reduced SHBG level.</span></span></span></span></p>"
      },
      {
        "id": 48611,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reduced serum insulin level.</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following serum values is NOT in favour of diagnosis of PCOS? </span></span></p>",
    "unique_key": "Q3927797",
    "question_audio": null,
    "question_video": null,
    "map_id": 18847,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Reduced serum insulin level</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LH level is elevated and/or ratio of LH: FSH is &gt; 3:1</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reversed estradiol: estrone ratio- The estrone level is markedly elevated.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SHBG level is reduced.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androstenedione level is elevated.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum testosterone and DHEA may be marginally elevated. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raised serum insulin level </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ratio of fasting glucose: fasting insulin is &lt; 4.5</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us review each option:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated LH, Ratio of LH/FSH is &gt; 3:1</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Elevated LH and a high LH/FSH ratio are common findings in PCOS. An elevated ratio often reflects the altered hormonal environment characteristic of PCOS </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reversible Estradiol: Estrone Ratio</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In PCOS, there can be an altered ratio of estradiol to estrone. This change is due to increased peripheral conversion of androgens to estrogens, particularly in adipose tissue. While this change can be seen in PCOS, it&#39;s not as specific or diagnostic as other hormonal alterations.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Reduced SHBG Level</strong>: Reduced levels of sex hormone-binding globulin (SHBG) are a typical finding in PCOS. Lower SHBG leads to higher levels of free androgens, contributing to the hyperandrogenism seen in PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced Serum Insulin Level</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct as the exception. PCOS is often associated with insulin resistance, which typically leads to elevated, not reduced, insulin levels. Reduced serum insulin levels would not typically support a diagnosis of PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In diagnosing PCOS, typical hormonal findings include elevated LH levels, a high LH/FSH ratio, reduced SHBG levels, and often elevated insulin levels due to insulin resistance. Reduced serum insulin levels are not characteristic of PCOS and would not support its diagnosis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 419, Speroff&rsquo;s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48611,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "InvestigationBased"
    ]
  },
  {
    "id": 12163,
    "choices": [
      {
        "id": 48616,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Clomiphene citrate</span></span></p>"
      },
      {
        "id": 48617,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cyclical progesterone tablets</span></span></p>"
      },
      {
        "id": 48618,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">OC pills containing levonorgestrel</span></span></p>"
      },
      {
        "id": 48619,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">OC pills containing cyproterone acetate</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 19-year-old unmarried girl presents with irregular periods, acne and facial hair. The best treatment for her is?</span></span></span></span></p>",
    "unique_key": "Q4112723",
    "question_audio": null,
    "question_video": null,
    "map_id": 18848,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. OC pills containing cyproterone</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PCOS is a heterogeneous syndrome complex characterized by chronic anovulation with androgen excess and frequently associated with insulin resistance, resulting in menstrual irregularity, infertility, acne and hirsutism.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptive pills are the first-line therapy drug of choice for PCOS patients with menstrual abnormalities and hirsutism, acne (Not wanting fertility)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OC pills will make the menstrual cycles regular and suppress acne and hirsutism.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyproterone is a progesterone with anti-androgenic properties and hence it is best for those patients who have androgen excess.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclical progesterone treatment will only regularize the cycles and will not help in treatment of acne and hirsutism.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Let us consider the best treatment options:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene Citrate</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Clomiphene citrate is primarily used for ovulation induction in women with infertility, particularly in those with polycystic ovary syndrome (PCOS). It is not the best choice for treating acne and hirsutism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclical Progesterone Tablets</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Cyclical progesterone can be used to regulate menstrual cycles in cases of anovulation or irregular periods. However, it doesn&#39;t directly address hyperandrogenism symptoms such as acne and facial hair.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>OC Pills Containing Levonorgestrel</strong>: Oral contraceptives containing levonorgestrel can regularize menstrual cycles and provide contraception. However, levonorgestrel is a more androgenic progestin and might not be the best choice for treating acne and hirsutism.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OC Pills Containing Cyproterone Acetate</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct. Oral contraceptive pills containing cyproterone acetate are effective in treating symptoms of hyperandrogenism such as acne and hirsutism, in addition to regulating menstrual cycles. Cyproterone acetate has anti-androgenic properties, making it particularly suitable for these symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In young women with symptoms of hyperandrogenism (such as acne and hirsutism) and irregular periods, oral contraceptive pills containing anti-androgenic progestins like cyproterone acetate are often the best treatment option. These pills help regulate menstrual cycles and directly address androgen-related symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 423, Speroff&rsquo;s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48619,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 12164,
    "choices": [
      {
        "id": 48620,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene citrate </span></span></span></span></p>"
      },
      {
        "id": 48621,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal acetate</span></span></span></span></p>"
      },
      {
        "id": 48622,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian drilling </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>"
      },
      {
        "id": 48623,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Letrozole</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not a treatment option for PCOS?</span></span></p>",
    "unique_key": "Q5268081",
    "question_audio": null,
    "question_video": null,
    "map_id": 18849,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Ulipristal acetate</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic ovary syndrome</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A diagnosis of PCOS must meet 2 out of 3 criteria (Rotterdam Criteria)</span></span></span></span>\r\n\t<ol>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Androgen excess with clinical hyperandrogenism or elevated serum free or total testosterone</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ovarian dysfunction with oligo/ anovulation </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic ovary morphology on ultrasound</span></span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lifestyle Modifications</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If the patient wishes to become pregnant (Desirous of fertility)</span></span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Letrozole: 1<sup>st</sup> line drug for ovulation induction</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene can also be used for ovarian stimulation.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin can improve menstruation but has little or no benefit in treating infertility; it is beneficial for metabolic or glucose abnormalities.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2<sup>nd</sup> line: gonadotropins and Laparoscopic ovarian drilling</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If the patient does not desire pregnancy: </span></span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Combined OCP</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medroxyprogesterone acetate, 10 mg daily orally for the latter half of the cycle (Day 15-25)</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The levonorgestrel-containing IUD is another option to minimize uterine bleeding and protect against endometrial hyperplasia.</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hirsutism</span></span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A low-dose combination oral contraceptive (progesterone component of the pill should preferably be cyproterone acetate or Drospirenone) for at least 6&ndash;12 months.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone is also useful in doses of 25 mg three or four times daily orally.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flutamide, 125&ndash;250 mg once daily orally, and finasteride, 5 mg once daily orally, are also effective</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Because spironolactone, flutamide, and finasteride are potentially teratogenic, they should only be used with secure contraception.</span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Topical eflornithine cream applied to affected facial areas twice daily for 6 months may be helpful.</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">let&#39;s summarize each option:</span></span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. A.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene Citrate</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Used for Induction of ovulation in women with PCOS, particularly those who are experiencing infertility. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. B.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal Acetate</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Correct as the exception. Ulipristal acetate is used as an emergency contraceptive and for the treatment of uterine fibroids. It is not a treatment option for PCOS, which requires management of symptoms like irregular menstrual cycles, hyperandrogenism, and insulin resistance.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ovarian Drilling</strong>: Ovarian drilling used particularly in women who do not respond to ovulation-inducing medications. It can help to restore ovulation by reducing ovarian androgen production.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option. D.</span></span></strong> <strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Letrozole</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Letrozole is used in the treatment of PCOS for ovulation induction, especially in women who are trying to conceive. It has been found to be effective in inducing ovulation and improving pregnancy rates in women with PCOS.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In the management of PCOS, common treatments include clomiphene citrate and letrozole for ovulation induction and ovarian drilling as a surgical option for those not responding to medication. Ulipristal acetate, used for emergency contraception and uterine fibroids, is not a treatment option for PCOS</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 424, Speroff&rsquo;s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</span></span></strong></span></span></p>",
    "correct_choice_id": 48621,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 12165,
    "choices": [
      {
        "id": 48624,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Letrozole</span></p>"
      },
      {
        "id": 48625,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Clomiphene citrate</span></p>"
      },
      {
        "id": 48626,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Metformin</span></p>"
      },
      {
        "id": 48627,
        "text": "<p><span style=\"color:black;font-size:12pt;\">Oral contraceptive pills</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 25-year-old lady with infertility, irregular menstrual cycles, and hirsutism, is diagnosed to have polycystic ovarian syndrome. All of the following are treatment options in this patient except:</span></p>",
    "unique_key": "Q8307930",
    "question_audio": null,
    "question_video": null,
    "map_id": 18850,
    "difficulty_level": "difficult",
    "subjects_id": [
      14
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D. OCPs</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">PCOS can be managed in women desirous of fertility with ovulation induction drugs</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">These include</span></p><ol><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Letrozole (drug of choice)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Clomiphene citrate</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Gonadotropins</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Other drugs like tamoxifen also have been used to cause ovulation induction in women with PCOS</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Metformin alone or in combination with clomiphene citrate helps induce ovulation especially in women with high insulin resistance</span></p></li></ol></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>OCPs can be given to women with PCOS with irregular cycle who ARE NOT desirous of fertility.</strong></span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Since this woman has infertility, OCPs should be the answer.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Let us look at the other options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"background-color:transparent;font-size:16px;\"><strong>Option A. Letrozole:</strong> it is the drug od choice for ovulation induction in PCOS.&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option. B.</strong></span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\"><strong>Clomiphene Citrate</strong>: Clomiphene citrate is a common first-line treatment for infertility in PCOS. It induces ovulation by blocking estrogen receptors, leading to increased FSH and LH production.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Metformin</strong>: Metformin is used in PCOS, especially in patients with insulin resistance. It can improve menstrual regularity and ovulation, and it is beneficial for metabolic aspects of PCOS.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In treating PCOS, clomiphene citrate and metformin are common options, especially when addressing infertility. OCPs are used for managing menstrual irregularities and hyperandrogenism but are not suitable for treating infertility due to their contraceptive nature. Tamoxifen is not typically used in PCOS treatment but can be used for ovulation induction.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ref: Page 424, Speroff\u2019s Clinical Gynecological Endocrinology and Infertility 9<sup>th</sup> edition</strong></span></p>",
    "correct_choice_id": 48627,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 41601,
    "choices": [
      {
        "id": 166088,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1b 2d 3c 4a</span></span></span></p>"
      },
      {
        "id": 166089,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1a 2d 3c 4b</span></span></span></p>"
      },
      {
        "id": 166090,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1a 2c 3d 4b</span></span></span></p>"
      },
      {
        "id": 166091,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1b 2c 3d 4a</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following correctly:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/screenshot-2024-04-24-113312.JPG\" style=\"height:201px; width:700px\" /></span></span></p>",
    "unique_key": "Q1352958",
    "question_audio": null,
    "question_video": null,
    "map_id": 24172,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B. 1a 2d 3c 4b</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Remember this very important table</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/screenshot-2024-04-24-113640.JPG\" style=\"height:737px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Remember this very important table</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/screenshot-2024-04-24-113640_kvczIXj.JPG\" style=\"height:737px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: DC Dutta&rsquo;s Textbook of Contraception</span></strong></span></span></p>",
    "correct_choice_id": 166089,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 41602,
    "choices": [
      {
        "id": 166092,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Disappearance of the Mullerian duct</span></span></span></p>"
      },
      {
        "id": 166093,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Differentiation of the Wolffian duct</span></span></span></p>"
      },
      {
        "id": 166094,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Differentiation of the gonad into the testes</span></span></span></p>"
      },
      {
        "id": 166095,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Disappearance of the ovary</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of the SRY gene will cause what important development in embryology?</span></span></p>",
    "unique_key": "Q5791449",
    "question_audio": null,
    "question_video": null,
    "map_id": 24173,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C. Differentiation of the gonad into the testes</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Normal Sex Development</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sex development starts in utero and continues in adult life with attainment of sexual maturity and reproductive capability</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Major determinants of sex development are</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chromosomal Sex (46XX or 46XY)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Gonadal sex (Testes or ovary)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenotypic sex (External genitalia)</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sex determination primarily begins by the presence or absence of the Y chromosome </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">On the Short arm of the Y chromosome, there is located the SRY gene (Sex Determining Region) &ndash; Yp11.3 and is the most important genetic aspect for sex determination and its presence or absence determines the direction of gonadal differentiation. </span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SRY activates several other genes that promote testis development. These include</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SOX 9</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fgf 9</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In 46 XX embryos, genes responsible include Wnt4 and Rspo 1.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The chromosomal sex determines the gonadal sex (i.e. whether the gonads will become testes or ovaries) in the embryo. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The gonads are BIPOTENT (Undifferentiated) till 5 weeks, they then differentiate into testes or ovaries based on whether the karyotype is 46XX or 46XY </span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">On the Short arm of the Y chromosome, there is located the SRY gene (Sex Determining Region) &ndash; Yp11.3 and is the most important genetic aspect for sex determination and its presence or absence determines the direction of gonadal differentiation. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SRY activates several other genes that promote testis development.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 166094,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 41603,
    "choices": [
      {
        "id": 166096,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">5 weeks</span></span></span></p>"
      },
      {
        "id": 166097,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">6 weeks</span></span></span></p>"
      },
      {
        "id": 166098,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">7 weeks</span></span></span></p>"
      },
      {
        "id": 166099,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">8 weeks</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A curious pregnant patient visits the antenatal OPD. She has missed her period by 4 days and her pregnancy test is positive. This is her 1<sup>st</sup> pregnancy and although, sex detection is banned in India, she is very curious about how the baby forms and asks if it is possible to know the sex of the baby now. You tell her that the gonads are undifferentiated at present. The gonads are bipotent till?</span></span></p>",
    "unique_key": "Q1792887",
    "question_audio": null,
    "question_video": null,
    "map_id": 24174,
    "difficulty_level": "intermediate",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. 5 weeks</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The gonads are BIPOTENT (Undifferentiated) till 5 weeks, they then differentiate into testes or ovaries based on whether the karyotype is 46XX or 46XY </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/screenshot-2024-04-24-113705.JPG\" style=\"height:204px; width:845px\" /></span></strong></span></span></p>",
    "correct_choice_id": 166096,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 41604,
    "choices": [
      {
        "id": 166100,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">45 XO gonadal dysgenesis</span></span></span></p>"
      },
      {
        "id": 166101,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">46 XX gonadal dysgeneses</span></span></span></p>"
      },
      {
        "id": 166102,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">46 XY gonadal dysgenesis</span></span></span></p>"
      },
      {
        "id": 166103,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">46 XXY gonadal dysgenesis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Swyer syndrome is an example of</span></span></span></p>",
    "unique_key": "Q1603829",
    "question_audio": null,
    "question_video": null,
    "map_id": 24175,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C. 46 XY gonadal dysgenesis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">46 XY Complete gonadal dysgenesis (Swyer syndrome)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Uncommon form of gonadal dysgenesis; 46XY karyotype</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The dysgenetic gonads don&rsquo;t produce AMH/ Androgens, so Phenotype is female. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">They have a normal uterus, fallopian tubes, cervix and vagina</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">No masculinization of external genitalia</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">15% mutation of SRY gene</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Majority: No cause identified</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Present as</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Primary amenorrhoea</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Delayed sexual maturation</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Normal pubic hair</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Normal female internal and external genitalia</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Diagnosis:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypogonadotrophic hypogonadism</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Karyotype</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Treatment</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sex of assignment and rearing: Female</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Gonadectomy soon after diagnosis</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Estrogen: to maintain sexual maturation and breast development</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pregnancy can be achieved with IVF with donor oocytes</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A: 45 XO gonadal dysgenesis: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is Turner syndrome</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B: 46 XX gonadal dysgenesis: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">There is no particular name but it includes ovarian dysgenesis leading to hypergonadotropic hypogonadism</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D: 46 XXY gonadal dysgenesis: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is Klinefelter syndrome</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">46 XY complete gonadal dysgenesis is Swyer syndrome</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 166102,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 41605,
    "choices": [
      {
        "id": 166104,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increased testosterone/ DHT ratio</span></span></span></p>"
      },
      {
        "id": 166105,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Decreased testosterone/ DHT ratio</span></span></span></p>"
      },
      {
        "id": 166106,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">No change in the testosterone/ DHT ratio</span></span></span></p>"
      },
      {
        "id": 166107,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Absent testosterone levels</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 14-year-old girl is brought to the OPD by her mother. She is of normal height, at the top of her class but her mother is concerned because of a sudden increase in hair growth and hoarseness of voice. She also mentions that she hasn&rsquo;t yet attained menarche. On examination, there is absent breast development and minimal presence of pubic and axillary hair. There is also increased facial hair growth and on local examination, there is an enlarged clitoris. An ultrasound reveals an absent uterus with the presence of gonad-like structures in the inguinal canal. Suspecting 5 alpha reductase deficiency, testosterone and DHT level is done. What is the expected finding in 5 alpha reductase deficiency?</span></span></span></p>",
    "unique_key": "Q3542643",
    "question_audio": null,
    "question_video": null,
    "map_id": 24176,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Increased testosterone/ DHT ratio</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation: </span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">5&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&alpha;&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Reductase Deficiency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Autosomal recessive</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Karyotype: 46XY </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Defective conversion of Testosterone to DHT (which is mediated by the enzyme 5 alpha reductase)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Testosterone (in fetal life): causes development of the internal male genitalia</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">DHT is responsible for external male genital development: Hence this does not develop as the enzyme mediating the conversion is absent/ deficient </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Classical presentation:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">External genitalia: predominantly Female at birth</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Internal genitalia: Male (The epididymis, the vas deferens, seminal vesicles and ejaculatory ducts form but empty into a short blind vagina)</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Testis: Located in the inguinal canal</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">At Puberty: Virilization of varying degrees</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Affected men develop a normal muscle mass, libido, deepening of voice (Testosterone dependent) but have less body hair, less temporal hairline recession, no acne (All these are DHT dependent) </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Diagnosis: </span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Suspect in infants with genital ambiguity</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Suspect in adolescence with the characteristic phenotype and a serum hormonal profile showing <strong>normal male level testosterone and an increased testosterone/ DHT ratio</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
    "correct_choice_id": 166104,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 41606,
    "choices": [
      {
        "id": 166108,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Perform 17 hydroxyprogesterone levels</span></span></span></p>"
      },
      {
        "id": 166109,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Perform testosterone and DHT levels</span></span></span></p>"
      },
      {
        "id": 166110,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urgent MRI brain</span></span></span></p>"
      },
      {
        "id": 166111,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Diagnostic laparoscopy to look at the gonads</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 23y primi delivers a baby. The pediatrician examines the baby and mentions that the genitalia is ambiguous and appears as shown. The gonads are not palpable. A karyotype done shows 46 XX karyotype. What is the next best step? </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/screenshot-2024-04-24-113725.JPG\" style=\"height:281px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q6629777",
    "question_audio": null,
    "question_video": null,
    "map_id": 24177,
    "difficulty_level": "beginner",
    "subjects_id": [
      14
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Perform 17 hydroxyprogesterone levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><u><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation</span></strong></span></span></u></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is a case of suspected congenital adrenal hyperplasia</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is the most common cause of ambiguous genitalia at birth</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In females (46 XX), there is excessive virilization. It presents as </span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Genital ambiguity, varying degrees of clitoral enlargement and labial fusion</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Internal genitalia: Normal because the excess androgens derive from the adrenals and the ovaries are normal (No AMH, no local high androgen)</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Diagnosis is by high levels of 17 OHP; In classical forms: Values &gt; 3500 ng/dl</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Adrenal crisis is common in the salt wasting form (Classical): &nbsp;Hypotension, hyponatremia, hyperkalemia, hypoglycemia, vomiting, diarrhea, weight loss</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hence in this scenario, to confirm the diagnosis, 17 OHP levels needs to be done. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B: Perform testosterone and DHT levels: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is done when suspecting Swyer syndrome where the testosterone levels are high and DHT levels are low. Also, in 46 XY hydroxylase deficiency, Testosterone levels are reduced.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C: Urgent MRI brain: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is indicated in precocious puberty</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D: Diagnostic laparoscopy to look at the gonads: </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This is again not indicated in the newborn and imaging can determine the presence or absence of gonads</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Androgen Excess: Congenital Adrenal Hyperplasia (CAH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Genetic Disorder caused by enzymatic defects in adrenal cortisol biosynthesis</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">3 main types</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">21 hydroxylase deficiency: MC</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">11&beta; hydroxylase</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">3&beta;-hydroxy dehydrogenase </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/24/obg-1-1.jpg\" style=\"height:501px; width:700px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In all 3 enzyme deficiencies, the pathophysiology relates primarily to </span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A decreased cortisol production, which stimulates a compensatory increase in pituitary ACTH causing adrenal hyperplasia. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Also, increased levels of steroid hormones proximal to the block seek an alternative metabolic pathway leading to increased levels of androgens</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In females (46 XX): </span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Genital ambiguity, varying degrees of clitoral enlargement and labial fusion</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Internal genitalia: Normal because the excess androgens derive from the adrenals and the ovaries are normal (No AMH, no local high androgen)</span></span></span></p>",
    "correct_choice_id": 166108,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "InvestigationBased"
    ]
  }
];
        let quizName = 'Amenorrhoea';
        let hierarchy = ["Cerebellum", "qBank", "Obstetrics & Gynaecology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>